Key Takeaways Vertex's BLA for povetacicept in adults with IgAN has been accepted by the FDA.The FDA is expected to make a decision on the application for povetacicept by Nov. 30, 2026.If approved, VRTX plans to launch povetacicept as a once-every-four-weeks at-home auto-injector. Vertex Pharmaceuticals (VRTX - Free Report) announced that the FDA has accepted its biologics license application (BLA) seeking approval for its investigational candidate, povetacicept, for treating adults with immunoglobulin A nephropathy (IgAN), a rare progressive kidney disease.
With the FDA accepting the BLA, a decision from the regulatory body is expected on Nov 30, 2026.
If approved, povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines, will become the first commercialized therapy in Vertex’s emerging nephrology franchise.
The company plans to launch povetacicept in a low-volume (<0.5 mL) subcutaneous auto-injector delivered once every four weeks via at-home administration, upon potential approval.
Year to date, shares of Vertex have lost 3.3% against the industry’s rise of 0.7%.
Image Source: Zacks Investment Research
VRTX’s Recent Development Activities With PovetaciceptBased on positive interim data from the RAINIER phase III study in IgAN, a rolling BLA filing for povetacicept for IgAN was completed in March 2026. Data from the RAINIER study showed that povetacicept led to a rapid, deep and sustained improvement in proteinuria (excess protein in the urine), a direct consequence of IgAN.
Vertex believes povetacicept has pipeline-in-a-product potential for B-cell-mediated diseases. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases.
Vertex is also conducting a pivotal phase II/III study of povetacicept for a second potential renal indication, primary membranous nephropathy (pMN). Vertex has also initiated a phase II study on povetacicept for treating generalized myasthenia gravis (gMG) in the first half of 2026.
Povetacicept was added to Vertex’s portfolio following the acquisition of Alpine in 2024. Vertex believes povetacicept holds significant commercial opportunities.
Growing Competition in the Targeted SpaceUpon potential approval, povetacicept is likely to face competition from the likes of Calliditas Therapeutics’ Tarpeyo, Novartis’ (NVS - Free Report) Fabhalta and Travere Therapeutics’ (TVTX - Free Report) Filspari.
Novartis’ Fabhalta is approved under the accelerated pathway for reducing proteinuria in adults with primary IgAN at risk of rapid disease progression. The NVS drug is also approved for complement 3 glomerulopathy and paroxysmal nocturnal hemoglobinuria indications.
Both Calliditas’ Tarpeyo and Travere’s Filspari are approved for a similar indication — to slow the decline in kidney function in adults with primary IgAN who are at risk of disease progression.
VRTX’s Zacks RankVertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 -
- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -
- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF) on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAFTA (elexacaftor/tezacaftor/ivacaftor). Vertex plans to submit for global regulatory approvals of ALYFTREK in children ages 2 to 5 in the first half of 2026, and the company has begun global regulatory submissions for TRIKAFTA in children ages 1 to <2.
“The data we’re presenting today bring us to the cusp of our 25-year mission to advance medicines that restore CFTR function to people living with CF,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “They show that ALYFTREK is the first medicine to bring the majority of children ages 2 to 11 to SwCl below 30 mmol/L, which is incredibly exciting because SwCl <30mmol/L is the median value seen in carriers who are known to have normal health and is a key marker of restoration of CFTR function.”
“As someone who has been treating people with CF for more than 20 years and whose center is involved in the ALYFTREK 2 to 5 years clinical program, I have seen firsthand how the medicine can help patients achieve better CFTR function through reduction in sweat chloride and improve other important markers of disease like exocrine pancreatic function,” said Professor Marcus A. Mall, M.D., Professor and Chair of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center at Charité Universitätsmedizin Berlin. “The findings add to the evidence base exploring CFTR modulation in very young children with cystic fibrosis. Taken together with existing data, these results underscore the rationale for studying treatments that aim to restore CFTR function as early as possible in the disease course.”
Data presented in children ages 2-5 treated with ALYFTREK
“A Phase 3 open-label clinical trial of vanzacaftor/tezacaftor/deutivacaftor in children aged 2-5 years with cystic fibrosis” was presented as a late-breaking abstract and oral presentation in the “Late-Breaking Science” session on June 5 from 5:00 p.m. to 6:30 p.m. GMT+1. Data from 67 children who all completed the 24-week, Phase 3, open-label study show that ALYFTREK was generally safe and well tolerated, consistent with the established safety profile. The primary endpoint of the study was safety and tolerability. Treatment with ALYFTREK resulted in a rapid, clinically meaningful improvement in CFTR function with a mean reduction in sweat chloride from a baseline on TRIKAFTA of -9.6 mmol/L (95% CI -12.1 to -7.0) through Week 24, with 92% of children achieving SwCl concentrations of <60 mmol/L (the diagnostic threshold for CF), and 65% of children reaching SwCl values of <30 mmol/L. These improvements in CFTR function surpass those seen in trials with any other CFTR modulator in this age group.
Longer-term data presented on ALYFTREK and TRIKAFTA
Vertex also presented multiple abstracts on clinical and real-world evidence on ALYFTREK and TRIKAFTA as listed below. These abstracts will be published in the Journal of Cystic Fibrosis:
“Long-term safety and efficacy of vanzacaftor/tezacaftor/deutivacaftor in people with cystic fibrosis aged 12 years and older: 96-week interim analysis from an open-label extension study.” (Poster 143) “Long-term safety and efficacy of vanzacaftor/tezacaftor/deutivacaftor in children with cystic fibrosis aged 6 years and older: 96-week interim analysis from an open-label extension study”; also presented as an oral presentation (WS01.3) during the symposium “Clinical and functional impact of highly effective modulators” on June 4 from 3:00–4:30 p.m. GMT+1. “Demographic and clinical characteristics of children with CF aged 2-5 years initiating ELX/TEZ/IVA in LONGITUDE — a UK CF Registry observational study.” (Poster P432) Data presented in children ages 1 to <2 treated with TRIKAFTA
“A Phase 3, 24-Week, Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis 12 to <24 Months of Age” (WS01.2) was featured in an oral presentation as part of the symposium “Clinical and functional impact of highly effective modulators” on June 4 from 3:00–4:30 p.m. GMT+1 and the abstract will be published in the Journal of Cystic Fibrosis:. Results from a 24-week, Phase 3, open-label study of TRIKAFTA in 54 enrolled children aged 12 to <24 months was presented. The primary endpoint was safety and tolerability. TRIKAFTA was generally safe and well tolerated; the safety data are consistent with the established safety profile. Treatment with TRIKAFTA in this age group resulted in rapid, statistically significant and clinically meaningful decrease in SwCl, with a mean reduction of -71.8 mmol/L from a baseline without CFTR modulator treatment through Week 24, with 98.0% of children achieving concentrations <60 mmol/L and 68.6% reaching <30 mmol/L.
The uses of ALYFTREK in children with CF 2 to 5 years old, and TRIKAFTA in children with CF 1 to <2 years old, are investigational.
U.S. IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR ALYFTREK AND TRIKAFTA
WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE
Elevated transaminases have been observed in patients treated with ALYFTREK.
TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in both clinical trials and the postmarketing setting in patients with and without a history of liver disease taking TRIKAFTA, a fixed-dose combination drug containing elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA), the same or similar active ingredients as ALYFTREK. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA.
Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every 3 months for the next 12 months, and at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test (LFT) elevations at baseline.
Interrupt ALYFTREK or TRIKAFTA for significant elevations in LFTs or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If resolved, resume treatment only if benefit is expected to outweigh risk. Closer monitoring is advised after resuming treatment.
ALYFTREK or TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). ALYFTREK or TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ALYFTREK or TRIKAFTA should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced dosage and monitor patients closely.
WARNINGS AND PRECAUTIONS
DRUG-INDUCED LIVER INJURY AND LIVER FAILURE
Elevated transaminases have been observed in patients treated with ALYFTREK. TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Liver failure leading to transplantation and death has been reported in patients with and without a history of liver disease taking TRIKAFTA. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA Assess LFTs in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every 3 months for the next 12 months, and at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or LFT elevations at baseline, or a history of elevated LFTs with drugs containing ELX, TEZ, and/or IVA Interrupt ALYFTREK or TRIKAFTA in the event of signs or symptoms of liver injury, which may include: Significant elevations in LFTs (e.g., ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN) Clinical symptoms suggestive of liver injury (e.g., jaundice, right upper quadrant pain, nausea, vomiting, altered mental status, ascites) Consider referral to a hepatologist and follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If resolved, and if benefit is expected to outweigh risk, resume treatment with close monitoring ALYFTREK and TRIKAFTA should not be used in patients with severe hepatic impairment, are not recommended in patients with moderate hepatic impairment, and should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced dosage and monitor patients closely HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS
Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported in the postmarketing setting for TRIKAFTA. If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue ALYFTREK or TRIKAFTA and institute appropriate therapy. Consider benefits and risks to determine whether to resume treatment PATIENTS WHO DISCONTINUED OR INTERRUPTED ELX-, TEZ-, OR IVA-CONTAINING DRUGS DUE TO ADVERSE REACTIONS
ALYFTREK
There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions. Consider benefits and risks before using ALYFTREK in these patients and if used, closely monitor for adverse reactions INTRACRANIAL HYPERTENSION (IH)
IH has been reported in the postmarketing setting with TRIKAFTA, which contains the same or similar active ingredients as ALYFTREK. Clinical manifestations of IH include headache, blurred vision, diplopia, and potential vision loss; papilledema can be found on fundoscopy. If an unusual headache or visual disturbances occur during treatment, and IH is suspected, interrupt treatment and refer for prompt medical evaluation. Consider benefits and risks to determine whether to resume treatment. Patients should be monitored until IH resolution and for recurrence. Patients with elevated vitamin A levels may be at increased risk NEUROPSYCHIATRIC EVENTS, INCLUDING SUICIDAL THOUGHTS AND BEHAVIORS
Serious neuropsychiatric events, including symptoms of anxiety, depression, suicidal ideation and behavior, and sleep disturbances, have been reported in the postmarketing setting in patients with and without a previous history of neuropsychiatric symptoms taking ALYFTREK or TRIKAFTA. Symptoms may occur within the first 3 months of treatment. Assess patients for baseline neuropsychiatric symptoms and monitor for new or worsening symptoms. Consider the benefits and risks to determine if treatment should be interrupted at symptom occurrence or resumed with symptom improvement DRUG INTERACTIONS
Use With CYP3A Inducers
Following concomitant use of strong or moderate CYP3A inducers with ALYFTREK, exposures of vanzacaftor, TEZ, and deutivacaftor were decreased, which may reduce ALYFTREK effectiveness. Concomitant use with strong or moderate CYP3A inducers is not recommended Exposure to IVA is significantly decreased and exposure to ELX and TEZ are expected to decrease with concomitant use of CYP3A inducers, which may reduce effectiveness of TRIKAFTA. Concomitant use with strong CYP3A inducers is not recommended Use With CYP3A Inhibitors
Exposure to vanzacaftor, TEZ, and deutivacaftor or ELX, TEZ, and IVA are increased when used concomitantly with strong or moderate CYP3A inhibitors. The dose of ALYFTREK or TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors CATARACTS
Non-congenital lens opacities have been reported in pediatric patients treated with TRIKAFTA, which contains IVA (similar to an active ingredient in ALYFTREK). Baseline and follow-up ophthalmological examinations are recommended in pediatric patients ADVERSE REACTIONS
ALYFTREK
Serious adverse reactions that occurred more frequently with ALYFTREK than with ELX/TEZ/IVA in 2 or more patients (≥0.4%) were influenza (1.5%), increased AST (0.4%), increased GGT (0.4%), depression (0.4%), and syncope (0.4%) The most common adverse reactions occurring in ≥5% of patients and at a frequency higher than ELX/TEZ/IVA by ≥1% were cough, nasopharyngitis, upper respiratory tract infection (URTI), headache, oropharyngeal pain, influenza, fatigue, increased ALT and AST, rash, and sinus congestion TRIKAFTA
Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo included rash (1% vs <1%) and influenza (1% vs 0%) The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA and at a rate higher than placebo by ≥1% were headache; URTI; abdominal pain; diarrhea; rash; increased ALT, blood creatine phosphokinase, AST, and blood bilirubin; nasal congestion; rhinorrhea; rhinitis; influenza; sinusitis; and constipation USE IN SPECIFIC POPULATIONS
PEDIATRIC USE
Safety and effectiveness have not been established for ALYFTREK in patients <6 years, nor for TRIKAFTA in patients <2 years. The use in children under these ages is not recommended INDICATIONS
ALYFTREK is indicated for the treatment of patients ≥6 years who have a clinical diagnosis of CF and ≥1 variant in the CFTR gene that is responsive based on clinical and/or in vitro data or results in CFTR protein production.
TRIKAFTA is indicated for the treatment of patients ≥2 years who have a clinical diagnosis of CF and ≥1 variant in the CFTR gene that is responsive based on clinical and/or in vitro data or results in CFTR protein production.
If the patient’s genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of ≥1 indicated variant.
Please see full U.S. Prescribing Information, including Boxed WARNING, for ALYFTREK and TRIKAFTA.
About Cystic Fibrosis
Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 112,000 people, including approximately 97,000 people in the United States, Europe, Australia and Canada. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving.
Learn more about the importance of sweat chloride (SwCl) in cystic fibrosis.
Today Vertex CF medicines are treating over 75,000 people with CF across more than 60 countries on six continents. This represents approximately 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements made by Carmen Bozic, M.D. and Marcus A. Mall, M.D., and statements about company’s expectations to initiate global regulatory submissions for ALYFTREK in children with CF ages 2 to 5 years in the first half of 2026, expectations for the clinical benefits of ALYFTREK and TRIKAFTA, and expectations for the global regulatory submissions for TRIKAFTA in children with CF ages 1 to <2 years. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the company may be unable to make the anticipated regulatory submissions on the expected timeline, or at all, that data from the company's research and development programs may not support registration or further development of its compounds due to safety, efficacy, and other risks, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
Listen to the audio version of this article (generated by AI).
Editor’s Note: Louis Navellier has been managing money through major market cycles for nearly five decades. He was in the room in 1999 — and when someone who lived through that moment tells me today’s AI market is starting to rhyme with it, I pay attention.
Louis is still bullish. So am I. But what he’s written below makes a compelling case — that the difference between investors who build real wealth through this boom and those who lose it in a pullback comes down to one thing: getting tactical before the volatility arrives, not after.
He’s hosting a free event on June 10 at 10 a.m. Eastern with TradeSmith CEO Keith Kaplan to show investors exactly how he’s approaching that — and there’s a free tool available right now that lets you check the short-term health of stocks you already own before the event even starts.
Register for that event here — and read what Louis has to say below.
In 1999, Jeff Bezos was doing something that drove Wall Street absolutely crazy.
Amazon.com Inc. (AMZN) was already a public company. And it was already capable of producing profits — if Bezos had wanted to. But instead, he kept aggressively reinvesting. Instead of worrying about profits, he was building warehouses, distribution infrastructure, and technology systems.
Every quarter, the margins that should have been there weren’t, because every dollar was going right back into the Amazon machine.
Analysts were furious. Where are the profits? What exactly are we owning here?
Meanwhile, all around Amazon, the dot-com boom was producing companies with no revenue, no product, sometimes no coherent business model at all — and their stocks were tripling. The whole market was chasing a story.
Who looks most like the future? Who has the best narrative? Wall Street was funding them fast and asking questions later.
Bezos wasn’t playing that game.
What he understood — and almost nobody else did back then — is that 1999 capital was a once-in-a-generation resource. Every dollar of market enthusiasm could be converted into permanent infrastructure: fulfillment capacity, distribution reach, systems that got cheaper the more volume they handled. He wasn’t optimizing for this quarter. He was building something that would be almost impossible to replicate once the window closed.
When the Music Stopped, the Infrastructure Survived When the music stopped in 2000, it stopped for everybody. The story companies – do I need to mention Pets.com? – vanished almost overnight.
Amazon went through its own brutal drawdown, but the infrastructure Bezos built was still there. The customer relationships were still there. The cost curves were still bending in the right direction.
By 2005, Bezos looked like a genius. In 1999, he just looked tactical.
I was managing money through all of it. And I’ll tell you — 1999 was one of the best years of my career. It was also one of the strangest markets I’ve ever seen in nearly 50 years in this business. Capital was flowing faster than fundamentals could justify.
My Stock Grader system kept me focused on what actually mattered: real earnings, real institutional conviction. A lot of the dot-com darlings never showed up in my system at all — and a lot of them went to zero.
But the companies with genuine fundamentals underneath the noise survived. And the ones — like Amazon — that used the window tactically didn’t just survive. They won the whole decade.
Right now, the AI boom is rhyming with that moment in ways that I find both exciting and instructive. But at the same time, this is not the dot-com boom — the fundamentals are far stronger.
So, in this piece, I want to show you why this AI boom reminds me so much of the late 1990s… why I believe some AI stocks could be much higher by year-end… and why the smartest move today is not to run for the exits when things get choppy, but to get more tactical.
And finally, I’ll tell you about a new tool that can help you do just that…
The ChatGPT Moment: What Lit the Fuse This Time I recently got my hands on a chart from our friends at Bespoke Investment Group comparing the Nasdaq Composite’s performance during the internet boom of the late 1990s with its current path during the AI boom.
The comparison is striking.
ChatGPT appears to have done for AI what Netscape did for the internet.
When Netscape came along, investors realized the internet wasn’t just a neat new technology. It was a business revolution. Money poured into the companies building that new world, and the Nasdaq soared.
We’re seeing that same basic story today.
ChatGPT woke people up to what AI can actually do. And Wall Street quickly figured out how much infrastructure that was going to require.
The fact is that the boom is backed by real sales, real earnings, and real order backlogs.
Look at Bloom Energy Corp. (BE), for example. The company helps make fuel cell generators, which data centers need to produce power on-site so they don’t have to rely on the electrical grid.
Bloom Energy’s current product backlog is about $6 billion, while its total backlog exceeds $20 billion.
At this rate, it will take years to deliver what is already in the pipeline. And Bloom Energy isn’t an outlier. This story is playing out across the AI and data center space.
Companies are receiving more orders than sales. That makes this a real capital spending cycle.
That is why I remain bullish. Personally, I think the AI and data center stocks across my premium services could be another 30% to 40% higher between now and the end of the year.
But that does not mean investors should get complacent.
Summer Volatility Is Coming — Don’t Let It Shake You Out August and early September tend to be volatile. Seemingly everyone on Wall Street and in Europe are on vacation, trading volume thins out, and unscrupulous short sellers come out of the woodwork.
So, I would not be surprised if the market gets bumpy.
In fact, Bespoke also shows that the Nasdaq took a significant dip between late May and October 1998 — right in the middle of what turned out to be a historic bull run. I wouldn’t be surprised to see something similar this summer.
But here’s the key insight: If the AI Revolution continues to follow the internet boom’s path, a summer pullback would not mark the end of this bull market. It could simply set the stage for much higher levels later in 2026 and beyond.
That is why I do not want you to follow the “sell in May and go away” crowd to the exits.
We remain in one of the best earnings environments of our lifetime. Analysts continue to revise estimates higher. Companies keep beating expectations. Fundamentally superior stocks with accelerating earnings and sales growth should continue to lead.
But there is a big difference between staying invested and just closing your eyes.
The late 1990s created tremendous wealth. But that market did not move in a straight line. Even great stocks got hit hard from time to time. The investors who panicked during those pullbacks often missed the biggest gains that came next.
That is the real risk this summer.
Not that a great stock has a bad week. The real risk is that you let a bad week scare you out of a great stock right before the next leg higher.
And that’s why I’ve been working with my friends over at TradeSmith on something special – something that’s specifically designed for times like this.
The Strategy for What Comes Next: Stay Bullish, Get Tactical In my view, the answer is simple: Stay bullish, but get tactical.
That means focusing on fundamentally superior companies. It means paying attention to earnings momentum, sales growth, and analyst revisions. It means having a better way to track whether the stocks you own are still healthy in the short term.
And it’s why I’ve been paying close attention to what my friends at TradeSmith have been building.
On Wednesday, June 10, at 10 a.m. Eastern, I’m teaming up with TradeSmith CEO Keith Kaplan for a special event.
Keith and his team have spent years building technology designed to help investors make more tactical decisions. And during this event, we’re going to show you a new AI-powered approach to navigating today’s faster-moving market.
I don’t want to give away the full story today. That is what the event is for. But here’s the basic idea…
If this market really is rhyming with the late 1990s, investors need to be prepared for two things at once:
They need to stay positioned for the upside, because I believe the AI Revolution still has much further to run. But they also need to be ready for volatility, because even the strongest bull markets can shake people out along the way. Before the event, you can even test-drive part of the technology for yourself. You can enter the ticker symbols of stocks you already own – or stocks you are thinking about buying – and see how the system evaluates their short-term health.
That is exactly the kind of tool I believe investors should have at their fingertips in a market like this.
When volatility picks up, you don’t want to guess. You don’t want to rely on fear. And you do not want to get shaken out of a great long-term opportunity because the market has a bad week.
That’s why I encourage you to sign up for our free event. And to try out the free ticker tool before the event.
Jeff Bezos didn’t close his eyes in 1999 and hope for the best. He got tactical.
That’s exactly what I’m asking you to do right now.
Bloom Energy stock is taking a hit today. Why is BE stock falling? What Is Driving Bloom Energy’s Stock Today?Bloom's setup is complicated by the same order expanding the 25% list to include steel racks and aluminum lithographic plates, keeping some components sticky on costs even as other categories get relief. That mix is why traders are treating Thursday's slide as digestion rather than a clean tariff win, especially with futures risk-off.
The broader macro message matters for BE because the tariff move is arriving alongside a factory resurgence increasingly tied to AI buildouts, not just trade policy. That backdrop can keep demand elevated for on-site, always-on power solutions even if the tape is choppy.
Bloom Energy Stock: Key Levels To WatchEven with Thursday's dip, Bloom's longer-term trend remains pointed higher: the stock is about 20.8% above its 50-day SMA ($231.78) and about 97.4% above its 200-day SMA ($141.86). The 20-day SMA remains above the 50-day SMA, and the 50-day SMA is above the 200-day SMA (a golden-cross structure that began in June 2025), which typically keeps pullbacks "buyable" as long as price doesn't lose key levels.
Near-term, the stock is now about 1.5% below its 20-day SMA ($284.32), which frames this premarket weakness as a test of the short-term trend line after the May breakout and May swing high. RSI is 54.91 (neutral), which matters because RSI measures how "stretched" the move is; here it suggests consolidation pressure rather than an overheated, blow-off top.
Key Resistance: $303.00 — a nearby round-number/pivot area where rebounds can stall, especially after slipping under the 20-day average zone Key Support: $249.00 — a prior buyer-defense area that sits closer to the stock's intermediate uptrend structure How Bloom Energy Operates and Makes MoneyBloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation. Its Bloom Energy Servers are fuel-flexible, able to run on natural gas, biogas and hydrogen, to deliver 24/7 electricity for stationary uses in the U.S. and internationally.
That business model is why tariff changes matter: fuel-cell and power-generation hardware tends to be metal- and component-intensive, so lower tariffs on certain steel, aluminum, and copper categories can help the cost side of building and delivering equipment.
Bloom Energy Benzinga Edge Scorecard BreakdownBelow is the Benzinga Edge scorecard for Bloom Energy, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Bullish (Score: 99.69) — The stock is still screening as a top-tier trend name despite the premarket pullback. Value: Weak (Score: 0.73) — The market is pricing in a lot of future upside, leaving little room for disappointment. Growth: Bullish (Score: 98.6) — Expectations remain geared toward strong expansion, which can keep buyers engaged on dips. The Verdict: Bloom Energy’s Benzinga Edge signal reveals a classic High-Flyer setup, with elite Momentum and Growth but very weak Value. For longer-term bulls, that usually means trend support matters more than "cheapness," while any break of key support can trigger sharper de-risking than investors expect.
Bloom Energy Stock Price Action In PremarketBE Stock Price Activity: Bloom Energy shares were down 2.86% at $279.10 during premarket trading on Thursday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
An updated edition of the April 16, 2026, article.
As industries worldwide increasingly embrace the global energy transition in pursuit of the 2050 net-zero goal, investment in clean energy has grown at an unprecedented pace over the past decade. To this end, the International Energy Agency (IEA) expects global investment in grids, storage, low-emission fuels, nuclear, renewables, efficiency, and electrification to reach nearly $2.2 trillion by the end of 2026, accounting for almost 65% of global energy investment this year.
Traditional growth catalysts, including record-low levelized costs of energy (LCOE) for wind and solar, supportive policy initiatives, and accelerating electric vehicle (EV) adoption, continue to provide a strong foundation for global clean energy expansion. Beyond these established drivers, a powerful new source of demand has emerged — the rapid buildout of AI infrastructure.
The energy-intensive data centers needed to train and operate large language models are creating significant incremental demand for electricity, positioning them as a major growth catalyst for the renewable energy industry.
The IEA highlights that tech giants became the largest corporate buyers of clean energy, accounting for roughly 40% of all global corporate renewable Power Purchase Agreements (PPAs) signed last year. With data center electricity consumption projected to nearly double by 2030, renewables should serve as the primary engine to meet this unprecedented load growth.
Beyond tech demand, severe geopolitical instability ongoing in the Middle East has triggered a critical global energy crisis, making energy security a top priority for decision-makers worldwide. This crisis has sharply exposed the fragility of traditional fossil fuel supply chains, driving an aggressive surge in renewable deployment, especially among import-dependent economies. Consequently, this geopolitical shock has transformed clean energy assets into a strategic vehicle for investors seeking to gain exposure to both structural growth trends and enhanced energy resilience.
Crucially, energy storage serves as the indispensable "missing link" in this clean energy architecture. By capturing surplus generation and discharging it during peak demand, battery energy storage systems (BESS) transform intermittent solar and wind into a dependable, 24/7 power supply while providing critical grid stabilization services to prevent outages.
As technology costs decline, batteries are making renewables an economically superior, reliable alternative to traditional fossil fuels. This economic edge, combined with the urgent need for grid flexibility amid the ongoing energy crisis, is driving unprecedented capital flows into the sector. According to the IEA’s World Energy Investment 2026 report, global investment in battery storage is projected to surpass a record-breaking $100 billion this year.
Amid this backdrop, you may consider adding core clean energy stocks like Bloom Energy (BE - Free Report) , Plug Power (PLUG - Free Report) and Vestas Wind Systems (VWDRY - Free Report) to your portfolio to reap the benefits of the booming renewable energy and energy storage space. Exposure to utilities such as Duke Energy (DUK - Free Report) may also offer a way to participate in the energy transition, as these companies continue to scale their renewable generation assets.
Ready to uncover more transformative thematic investment ideas? Explore 37 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.
4 Renewable Energy & Battery Storage Stocks to BuyBloom Energy specializes in on-site, non-combustion solid oxide fuel cell (SOFC) technology, providing 24/7, low-carbon electricity for data centers, microgrids, and industrial use. Over the years, the company has grown its footprint to nearly 682 megawatts (MW) of deployed systems in the United States.
On April 13, 2026, BE announced an expanded partnership with Oracle to support the rapid buildout of its AI and cloud computing infrastructure. Under a master services agreement, Oracle intends to procure up to 2.8 gigawatts (GW) of Bloom’s fuel cell systems.
This reflects the solid demand that Bloom Energy’s fuel cell systems enjoy in the renewable energy market.
The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company’s 2026 sales implies year-over-year growth of 80.3%. The Zacks Consensus Estimate for BE’s 2026 earnings reflects a year-over-year improvement of 151.3%.
Plug Power specializes in building an end-to-end green hydrogen ecosystem that spans production, storage, delivery and power generation, helping customers achieve their business objectives while advancing decarbonization efforts.
With more than 74,000 fuel cell systems deployed and over 280 fueling stations installed globally, the company has established a leading position in the hydrogen economy. It is also the largest buyer of liquid hydrogen worldwide. The company is currently developing multiple green hydrogen production plants across North America and Europe, targeting commercial operation by year-end 2028.
On May 20, 2026, the company announced that the 30-megawatt (MW) Barrow Green Hydrogen project in Barrow-in-Furness, Cumbria (UK), where it is supplying electrolyzers, has reached a final investment decision (FID). Under the finalized agreement, Plug will supply 30 MW of its GenEco Proton Exchange Membrane (“PEM”) electrolyzers.
These developments represent Plug Power’s position as a prime supplier of PEM electrolyzers globally.
The stock boasts a four-quarter average earnings surprise of 13.03%. The Zacks Consensus Estimate for this Zacks Rank #2 (Buy) company’s 2026 sales implies year-over-year growth of 14.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vestas Wind Systems is a renowned designer, manufacturer, installer, and service provider for wind turbines across the globe. In mid-December 2025, Vestas reached 200 GW of installed wind turbines globally with the installation of a V172-7.2 MW turbine in Germany.
On June 1, 2026, the company announced that it had received an order to deliver 50 MW of wind turbines to Germany and 45 MW of wind turbines to the United Kingdom. These orders are indicative of the strong demand that VWDRY’s wind turbines enjoy worldwide.
The Zacks Consensus Estimate for this Zacks Rank #2 stock’s 2026 sales implies year-over-year growth of 16.4%. The stock boasts a long-term (three-to-five years) earnings growth rate of 14.90%.
As a diversified energy provider serving North America through a wide range of electric and natural gas businesses, Duke Energy has accelerated the expansion of its renewable energy portfolio in recent years. The company currently has more than 11,900 MW of renewable generation capacity in operation.
DUK aims to bring 4,000 MW of new solar and 5,600 MW of battery storage in service by 2034. As part of its clean energy portfolio expansion strategy, the company also targets to bring 1,200 MW of onshore wind in service by 2033, as well as 800-1,100 MW of offshore wind by 2034 and 2,200-2,400 MW by 2035.
On May 20, 2026, Duke Energy announced the completion of the Jumper Creek Solar Complex in Sumter County, which is part of the company’s plan to build 900 megawatts (MWs) of solar power in Florida by the end of 2028.
These initiatives reflect this Zacks Rank #2 stock's long-term strategy of delivering safe, reliable, affordable, clean and equitable energy to its customers. The Zacks Consensus Estimate for DUK’s 2026 sales implies year-over-year growth of 4.3%. The Zacks Consensus Estimate for the stock’s 2026 earnings suggests a year-over-year improvement of 6.3%.
Bloom Energy (BE - Free Report) closed at $263.61 in the latest trading session, marking a -9.53% move from the prior day. This move lagged the S&P 500's daily loss of 2.65%. Meanwhile, the Dow lost 1.35%, and the Nasdaq, a tech-heavy index, lost 4.18%.
Shares of the developer of fuel cell systems have appreciated by 12.65% over the course of the past month, outperforming the Oils-Energy sector's loss of 3.06%, and the S&P 500's gain of 5.47%.
The investment community will be paying close attention to the earnings performance of Bloom Energy in its upcoming release. The company's earnings per share (EPS) are projected to be $0.35, reflecting a 250% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $766.88 million, up 91.13% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $1.91 per share and a revenue of $3.65 billion, demonstrating changes of +151.32% and +80.33%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Bloom Energy. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Bloom Energy is currently sporting a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Bloom Energy is currently trading at a Forward P/E ratio of 152.55. This indicates a premium in contrast to its industry's Forward P/E of 17.69.
The Alternative Energy - Other industry is part of the Oils-Energy sector. This industry, currently bearing a Zacks Industry Rank of 105, finds itself in the top 44% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Bloom Energy (BE +4.27%) has blossomed over the past year. Its advanced fuel cells have become the power solution of choice for energy-hungry data center developers. Robust demand for its offerings has powered a tremendous revenue surge, enabling the company to become increasingly profitable.
That has powered a blistering surge in the hydrogen stock, which has rocketed 1,470% over the last 12 months. As a result, it now trades at a rich valuation of 22 times sales and 135 times forward earnings. That's a bit too rich for my liking. While I want to be a long-term investor in Bloom Energy, I don't want to buy shares at the current lofty valuation. Here's my strategy to buy shares at a lower price, or at least earn some income from the high-powered energy stock.
Image source: The Motley Fool.
Why I like Bloom Energy Bloom Energy is emerging as a key enabler of the AI infrastructure boom. Data centers need a tremendous amount of power to run the compute infrastructure necessary to support AI applications. AI data center power demand in the U.S. alone could surpass 100 gigawatts (GW) by 2035, triple last year's level of 31 GW.
Securing power is becoming a major bottleneck in holding back data center expansion. That's leading large-scale data center developers to partner with Bloom Energy to help accelerate their development efforts. For example, cloud computing giant Oracle recently expanded its partnership with Bloom Energy to deploy up to 2.8 GW of fuel cell capacity to accelerate its AI infrastructure build-out. Meanwhile, Brookfield Asset Management formed a $5 billion AI infrastructure partnership with Bloom Energy late last year to deploy advanced fuel cells at AI factories (specialized AI data centers). As founder and CEO KR Sridhar stated in the first-quarter earnings press release, "Bloom is rapidly becoming the standard and 'go-to choice' for on-site power." The company expects to grow revenue by 80% this year, an acceleration from its initial expectation of 60%.
Today's Change
(
4.27
%) $
10.62
Current Price
$
259.50
Cashing in while I wait for a pullback I missed the massive rally in Bloom Energy stock because I wasn't sure whether it would fully capitalize on the AI data center power opportunity. However, it has quickly emerged as a leader in providing on-site power solutions for AI data centers. AI power is one of my highest conviction investment themes, which is why I'd like to add Bloom Energy to my portfolio.
However, I don't want to buy shares at any price. That's leading me to write put options to potentially buy the stock at a lower price while earning income. Due to the stock's high volatility, I was recently able to write puts on Bloom Energy to buy shares nearly 50% below the current price while still earning an attractive options premium payment. If shares crash over the next few months, I can buy them at that much lower price or potentially roll my options contract forward for more income. Meanwhile, if Bloom stock is above my strike price at expiration, I should be able to write new options to earn more income. The biggest downside is that if Bloom Energy's shares continue to skyrocket, I would miss out on those gains.
Earning income on a stock I like I aim to keep about 10% of my portfolio in cash, half of which I use to write put options on the stocks I'd like to buy at lower prices. This strategy generates income on stocks I'd like to own if their prices come down, which I use to buy other stocks. Bloom Energy certainly fits this strategy. Its options pay very well, and it's an emerging leader in one of my highest-conviction investment themes that I'd love to buy at a lower price.
Matt DiLallo has positions in Brookfield Asset Management and has the following options: short August 2026 $150 puts on Bloom Energy. The Motley Fool has positions in and recommends Bloom Energy, Brookfield Asset Management, and Oracle. The Motley Fool has a disclosure policy.
Bloom Energy shares are trending higher. Why is BE stock advancing? What’s Driving Bloom Energy’s Stock Today?The latest policy shift cuts tariffs on some steel and aluminum derivative products to 15% from 25%, effective for goods imported after 12:01 a.m. EST on June 8 and running through Dec. 31, 2027. It also creates a 10% tariff lane for foreign firms whose capital equipment is at least 85% U.S. "melted and poured" by weight, a detail that can influence sourcing decisions across industrial supply chains.
Even with the relief, the order also expands the 25% list to include items like steel racks and aluminum lithographic plates, which keeps parts of the cost picture "sticky" for component-heavy hardware. That mixed message is why the stock can trade more like a digestion move than a clean "tariff win," even as the longer-term demand story for on-site power stays in the conversation.
Bloom Energy has been trading the tariff headline as a swing factor for hardware economics, but the bigger "why now" is demand tied to factory activity and AI-linked buildouts that need always-on power. That demand angle can keep BE in play even when tariff relief is partial rather than broad-based.
S&P 500 futures are gaining 0.8% in premarket trading, setting a constructive tone for higher-beta names. For BE, that matters because the stock has been trading like a momentum-led industrial story, so it tends to respond quickly when risk appetite improves before the bell.
Critical Price Levels To Watch For BEThe bigger-picture trend is still up, but the near-term setup is more of a reset: BE is trading 6.3% below its 20-day SMA ($284.87) while staying 12.7% above its 50-day SMA ($236.95). That "below the short-term, above the intermediate-term" posture often defines consolidation phases after a strong run.
RSI is 47.29, which is neutral and suggests the stock isn't stretched in either direction right now; RSI is a momentum gauge that helps show whether buying or selling has become overheated. In this context, it reads more like a pause after May's swing high than a breakdown, especially with the 20-day SMA still above the 50-day SMA and a golden-cross structure (50-day above 200-day) in place since June 2025.
Key Resistance: $303.00 — a nearby round-number/pivot area where rebounds can stall, especially with price still under the 20-day average zone Key Support: $249.00 — a prior buyer-defense area that also sits near the stock's intermediate uptrend structure above the 50-day SMA ($236.95) Zooming out, the 12-month gain of 1130.10% explains why pullbacks can stay "buy-the-dip" oriented as long as the stock holds higher lows (the most recent swing low was in March). The 52-week range ($19.97 to $322.83) also frames $303.00 and the May peak zone as the next big overhead area traders will watch if momentum re-accelerates.
How Bloom Energy Operates In Power GenerationBloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation. Its Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications, with sales in the United States and internationally.
That business model is why tariff details can matter to the stock: fuel-cell and power-generation systems are hardware-heavy, and changes in steel and aluminum costs can flow into build-and-deliver economics. At the same time, the company's pitch into "always-on" power ties into a broader factory and data-driven buildout theme, which can keep demand resilient even when the tape gets choppy.
Bloom Energy’s Benzinga Edge Scorecard BreakdownBelow is the Benzinga Edge scorecard for Bloom Energy, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Bloom Energy’s Benzinga Edge signal reveals a classic High-Flyer setup, with momentum and growth doing the heavy lifting while value screens as very weak. For longer-term holders, that usually means trend and key support levels matter more than valuation anchors, especially heading into the next earnings cycle.
Bloom Energy Stock Price Movement In PremarketBE Stock Price Activity: Bloom Energy shares were up 1.63% at $267.91 during premarket trading on Monday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Shares of Bloom Energy (BE +4.27%) shot 10.7% higher within minutes of the market's opening on Tuesday but gave up all of those gains rapidly as the day progressed. As of 2 p.m. ET, the hydrogen stock was barely in the green.
Bloom Energy stock rose on speculation, but it's worth knowing what it was.
Image source: Getty Images.
The two catalysts that sent Bloom Energy stock soaring The S&P Dow Jones indexes has officially announced that Marvell Technology and Flex will be added to the S&P 500, effective prior to the market's opening on June 22, 2026.
Bloom Energy is not being added, but speculation is ripe that it could be next in line, now that its market capitalization is hovering at $70 billion. The stock also fulfills the other criteria required to join the S&P 500 index, including float, trading volume, and profitability in the last four quarters combined.
In late April, Bloom Energy reported 130% year-over-year growth in revenue and net income of $70 million for its first quarter. That profit means Bloom Energy is now profitable on a rolling four-quarter GAAP basis.
When a company is added to the S&P 500, passive index funds and exchange-traded funds are obligated to buy shares to mirror the index, and that anticipation likely drove Bloom Energy shares higher today.
Today's Change
(
4.27
%) $
10.62
Current Price
$
259.50
Also, Canaccord Genuity may have played a role in the hydrogen stock's early morning spike. Canaccord analyst George Gianarikas upgraded rival FuelCell Energy (FCEL 2.46%) stock to buy, raising its price target significantly from $12 per share to $30 per share. Gianarikas expects FuelCell to secure a major data center contract in the coming months, and believes the company could replicate Bloom Energy's commercial success and become an important supplier to the power-hungry artificial intelligence (AI) data center market.
What this means for Bloom Energy stock Regardless of whether Bloom Energy stock joins the S&P 500 or not, it remains a compelling buy.
Although the specific analyst upgrade and massive price target hike were handed over to a rival, they validate the fuel cell addressable market and confirm Bloom Energy's position as the industry bellwether. The company is also firing on all cylinders, projecting nearly 80% growth in revenue for 2026. Among its latest contracts, Bloom Energy expanded its partnership with tech giant Oracle to supply up to 2.8 gigawatts of fuel cell systems for its AI projects.
Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy, Marvell Technology, and Oracle. The Motley Fool recommends Flex. The Motley Fool has a disclosure policy.
Bloom Energy stock is showing weakness. Why is BE stock retreating? What Is Driving Bloom Energy’s Valuation Concerns?Bloom Energy has also been trading a "mixed relief" read-through on tariffs: while some inputs moved to 15% from 25%, the 25% list expanded to include items like steel racks and aluminum lithographic plates, keeping parts of the cost stack sticky. That nuance has been a key reason BE can trade like a digestion move even on policy headlines.
With futures softer pre-bell, high-beta names that have already had outsized runs can see sharper air pockets as traders trim exposure. That backdrop can amplify any "overvalued" framing, even if the longer-term trend is still intact.
Critical Price Levels To Watch For BEFrom a trend perspective, BE is still in a powerful uptrend, up 1100.23% over the past 12 months and trading 74.7% above its 200-day SMA ($146.30). The more immediate story is consolidation: the stock is 9.8% below its 20-day SMA ($283.28) but 5.7% above its 50-day SMA ($241.88), a common "digesting gains" setup after a sharp advance.
Momentum looks more neutral than stretched, with RSI at 47.07—RSI measures how extended a move is, and readings near the middle often line up with range-trading rather than a runaway trend. The moving-average structure still leans bullish with the 20-day SMA above the 50-day SMA, and the golden cross that formed in June 2025 keeps the longer-term bias pointed higher unless price starts losing the 50-day area.
Key Resistance: $303.00 — a round-number zone near the 20-day averages where rebounds can stall Key Support: $249.00 — a nearby floor that's also sitting above the 50-day SMA ($241.88), a common dip-buy area in strong trends How Bloom Energy Operates in the Clean Energy SectorBloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation. Its Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to produce 24/7 electricity for stationary applications.
That mix keeps the stock closely tied to policy expectations and supply-chain inputs, which is why tariff rules and legislative deadlines can move the narrative quickly. When shares are this far above long-term moving averages, valuation commentary can also hit harder because the market is already pricing in a lot of future execution.
Bloom Energy Benzinga Edge Scorecard AnalysisBelow is the Benzinga Edge scorecard for Bloom Energy, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Bloom Energy’s Benzinga Edge signal reveals a classic High-Flyer setup—very strong momentum and growth paired with a very weak value profile. In practice, that often means the trend can stay constructive, but volatility can spike quickly when valuation narratives take over.
Bloom Energy Stock Price Activity TodayBE Stock Price Activity: Bloom Energy shares were down 2.77% at $252.42 during premarket trading on Wednesday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Bloom Energy (BE +4.27%) stock has been on a blistering run this year, up over 198% as of June 9. Investors are excited that the on-site power generation company is starting to turn revenue into profits.
Over the week, however, Bloom shares have dipped more than 13%. While seemingly not based on any company-specific news, there is a reasonable potential explanation for the pullback.
Image source: Getty Images.
The likely reason for the pullback Bloom Energy reported Q1 revenue climbed more than 130% year over year to $751 million. Even more exciting was the $70.6 million in net income for the quarter compared to the $23.8 million loss from the same time a year ago. The stock price was already flying high for the year, but that first-quarter report helped send it into overdrive. On April 28, the day of the report, Bloom opened at around $228. By May 6, it was $299, a gain of more than 31%.
Shares still trade above where they were the morning of the earnings report, but they have recently pulled back. The recent stock slide appears to be more about short-term traders locking in profits than anything else.
Today's Change
(
4.27
%) $
10.62
Current Price
$
259.50
Time to buy the dip? Based on traditional metrics, Bloom stock is overvalued, with a forward price-to-earnings (P/E) ratio of 143. As a point of comparison, Nvidia, which often has its own lofty expectations to meet, has a forward P/E of 23. Still, any stock price drop could be an opportunity for long-term investors comfortable with growth stocks, especially if it isn't related to negative, company-specific news.
Bloom's proposition of on-site power that can be deployed in as little as 90 days is resonating with companies in the artificial intelligence field, including cloud infrastructure provider Oracle. But Bloom also counts the media and telecommunications conglomerate Comcast and the home improvement retailer Home Depot as its customers. Even as shares have climbed as high as they have this year, for investors who typically hold stocks for years or decades, there's still upside potential ahead.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy, Home Depot, Nvidia, and Oracle. The Motley Fool recommends Comcast. The Motley Fool has a disclosure policy.
Shares of Bloom Energy (BE +4.27%) plunged on Wednesday and were trading 10% lower as of 1:30 p.m. ET.
With the hydrogen stock surging a jaw-dropping 990% in one year after accounting for today's sell-off, it had become extremely stretched on valuations and looked ripe for a correction.
Today, though, a wild drama unfolded, sending Bloom Energy stock tanking.
Image source: Getty Images.
The curious case of the Cheyenne project The bullish thesis for Bloom Energy is heavily tied to the artificial intelligence (AI) data center build-out, which requires massive amounts of stable, uninterrupted power that Bloom's solid-oxide fuel cell servers can deliver. The company, for instance, recently extended its partnership with Oracle to supply up to 2.8 gigawatts of fuel cell systems for the tech giant's AI projects.
A Bloomberg report on Tuesday stated that Crusoe Energy has paused development of a 1.8 gigawatt (GW) data center in Cheyenne, Wyoming, at the "request" of a customer. Crusoe develops data centers for companies like Microsoft and OpenAI.
Here's how it all ties back to Bloom Energy: the company was selected to supply its fuel-cell systems for the first phase of the Cheyenne project. When the 1.8 GW facility was announced, there were claims that it was designed to scale to 10 GW.
In short, any pause, delay, or termination of such projects poses a direct risk to Bloom Energy's pipeline and revenue potential. That is why the stock plunged today.
But, wait.
Something interesting just happened that Wall Street is overlooking.
Today's Change
(
4.27
%) $
10.62
Current Price
$
259.50
In a statement this morning, utility giant Black Hills (BHK +0.28%), which is providing grid infrastructure for the Cheyenne project, confirmed that it hasn't been paused. Although Crusoe is no longer developing the project, Black Hills says it is now working directly with the large-load customer and expects the project to begin by early 2028, as planned.
What does this mean for Bloom Energy stock? So what does all of this mean for Bloom Energy? If the unnamed customer remains committed to the Cheyenne project as Black Hills says, there's no loss to Bloom Energy.
However, the development highlights a risk that has increasingly concerned investors: a potential slowdown in AI spending. When a high-profile project suddenly changes course, even if it remains active, investors begin to question whether more data center developments could face delays or hurdles.
These are exactly the kinds of days when pricey stocks like Bloom Energy, that are purely riding the AI wave, take a big beating.
Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy, Microsoft, and Oracle. The Motley Fool has a disclosure policy.
Bloom Energy (BE +4.27%) stock has slumped about 24% from its recent peak. The catalyst is waning AI optimism due to the potential for resurgent inflation and rising interest rates to slow AI-related capex spending. That could impact demand for Bloom Energy's advanced fuel cells, which are helping accelerate the deployment of AI infrastructure.
Here's a look at whether the hydrogen stock's recent slump makes it impossible to ignore right now.
Image source: The Motley Fool.
Capitalizing on the power surge AI is driving surging electricity demand. According to a Goldman Sachs estimate, U.S. data center power demand will more than double by 2027, rising from 31 gigawatts (GW) last year to 66 GW. AI data center power demand should continue to grow briskly over the next decade.
Power is one of the biggest bottlenecks in data center development. That plays right into Bloom Energy's hands, as its advanced fuel cells are fast-to-deploy on-site power solutions. For example, last year it delivered a fully operational fuel cell system to Oracle in just 55 days, more than a month ahead of its anticipated 90-day deployment schedule. That impressed the cloud giant, which expanded its strategic partnership with Bloom Energy to deploy up to 2.8 GW of its fuel cells to accelerate its AI infrastructure build-out. Bloom also formed a $5 billion strategic AI infrastructure partnership with Brookfield Asset Management last year to deploy its fuel cells into AI factories (specialized AI data centers).
Today's Change
(
4.27
%) $
10.62
Current Price
$
259.50
The investment proposition Those strategic partnerships are helping power robust growth for Bloom Energy. The company's revenue rocketed 130% in the first quarter to more than $750 million. Meanwhile, it produced $72.2 million in operating income (a $91.3 million jump) and generated $73.6 million in cash from operating activities (a $184.3 million year-over-year increase). Bloom expects to record between $3.4 billion and $3.8 billion in revenue this year, an 80% increase from last year at the midpoint (an acceleration from its initial expectation of 60% revenue growth), with improving profitability.
Bloom Energy's founder and CEO, KR Sridhar, believes his company is "ushering in the era of digital power for the digital age [and] rapidly becoming the standard and "go-to choice" for on-site power." That belief, along with the company's surging revenue and earnings, has helped power a big rise in the stock over the past year. Shares are up nearly 1,000% despite the recent 24% dip.
As a result, Bloom still trades at a premium valuation. It currently fetches nearly 18 times sales and over 110 times earnings. For comparison, that's higher than some of the fast-growing AI semiconductor and memory stocks:
NVDA PS Ratio (Forward) data by YCharts
Bloom Energy would have to continue delivering accelerated growth to justify that valuation multiple. If it runs into a speedbump, shares could take a tumble as investors lower their lofty expectations.
Bloom Energy is intriguing, but expensive Bloom Energy is becoming the partner of choice for AI data center developers seeking a rapidly deployable power solution. That's driving robust growth for the advanced fuel cell maker. However, investors have already priced in significant growth. So, while the recent decline in Bloom's stock makes it more interesting, it's not yet to the point of being impossible to ignore.
Matt DiLallo has positions in Broadcom and Brookfield Asset Management and has the following options: short August 2026 $150 puts on Bloom Energy. The Motley Fool has positions in and recommends Bloom Energy, Broadcom, Brookfield Asset Management, Micron Technology, Nvidia, and Oracle. The Motley Fool has a disclosure policy.
Bloom Energy shares are powering higher. Why is BE stock up today? What Is Driving Bloom Energy’s Valuation Debate?Bloom is also trading the nuance inside that tariff framework: a 10% tariff lane exists for capital equipment that is at least 85% U.S. "melted and poured," a detail that can swing sentiment for hardware-heavy supply chains. At the same time, parts of the 25% list expanded to include items like steel racks and aluminum lithographic plates, keeping the input-cost debate alive.
Critical Price Levels To Watch For BEZooming out, the trend is still pointed higher—BE is up 990.77% over the past 12 months and is trading 66.1% above its 200-day SMA ($147.23), with a golden cross in June 2025 keeping the longer-term structure bullish. The nearer-term story is digestion: the stock is trading 13% below its 20-day SMA ($280.96) but is essentially sitting on its 50-day SMA ($244.18), a common "cool-off" setup after a sharp advance.
For momentum, MACD is the cleaner read right now: it's below its signal line and the histogram is negative, which suggests upside pressure is cooling unless buyers can rebuild momentum. (RSI previously pushed into overbought territory in May, which fits the idea that the stock has been working off an overheated stretch.)
Key Support: $242.00 — a nearby pivot area sitting just under the 50-day SMA ($244.18), where dip-buyers often try to defend trend structure How Bloom Energy Generates Power and RevenueBloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation. Its Bloom Energy Servers are fuel-flexible and can use natural gas, biogas and hydrogen to generate 24/7 electricity for stationary applications.
Bloom Energy Benzinga Edge Scorecard AnalysisBelow is the Benzinga Edge scorecard for Bloom Energy, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Bloom Energy’s Benzinga Edge signal reveals a classic High-Flyer setup—very strong momentum and growth paired with extremely weak value. For longer-term holders, that usually means trend support levels matter more than "cheapness," because sentiment can turn quickly if the growth narrative wobbles.
Bloom Energy Stock Price Movement on ThursdayBE Stock Price Activity: Bloom Energy shares were up 4.64% at $245.09 at the time of publication on Thursday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Issued on behalf of LIXTE Biotechnology Holdings, Inc.
America can build data centers in months, but the electricity to run them can take half a decade to arrive. That gap is becoming one of the biggest investment stories of the decade — and a NASDAQ-listed company is repositioning itself to sit right inside it.
BOCA RATON, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — For two years, the story of the artificial-intelligence boom has been told in chips: who designs them, who fabricates them, who can buy enough of them. But a quieter, harder constraint has been forming underneath all of it, and it has nothing to do with silicon. The bottleneck that increasingly decides whether a data center, a factory, or an industrial site can actually come online is far more old-fashioned: electricity, delivered to the right place, at the right time. In boardrooms and grid-control rooms across North America, a phrase has started to take hold — power availability — and it is rapidly becoming one of the defining economic challenges, and investment themes, of the coming decade.
The numbers behind that challenge are stark. Roughly 2.3 terawatts of generation and storage capacity are currently sitting in U.S. interconnection queues — projects waiting for permission to plug into the grid — while the time it takes to develop new capacity in many regions has stretched from about two years historically to five to seven years or longer. The North American Electric Reliability Corporation has projected that summer peak demand will climb by 224 gigawatts over the next decade and has warned that several major grid regions face elevated risk of supply shortfalls. The problem, increasingly, is not whether power can be generated. It is whether power can be delivered where it is needed, when it is needed.
It is against that backdrop that LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) has announced a definitive agreement to acquire NOMAD Transportable Power Systems, Inc. — a company that describes itself as the market leader in deployable, utility-grade battery energy storage, and the first to bring a mobile, utility-grade 1 megawatt battery system to market. Upon closing, LIXTE intends to rename itself NOMAD Power Solutions and operate as what it calls a pure-play “power availability platform.” It is an unusual transformation, and a revealing one: a company is betting its entire future on the idea that getting power to where it is needed has become a business in its own right.
Why “Availability” Became the Word That Matters
For most of the modern grid’s history, the energy conversation centered on generation and price — how to make enough power, cleanly, cheaply. The AI era has scrambled that framing. Hyperscale data centers, reshored factories, and electrified transport are all demanding enormous blocks of electricity on timelines measured in months, not years. But the infrastructure that delivers power — transmission lines, substations, interconnection approvals — moves at the pace of permitting and construction, which is to say slowly. The result is a widening gap between when capacity is needed and when the grid can actually provide it.
That gap is the entire premise of the deployable-power thesis. If a permanent grid connection is years away, the argument goes, then the ability to roll in utility-grade electrical capacity quickly — as transportable equipment rather than fixed infrastructure — becomes enormously valuable. It is the difference between a project that can launch this year and one that waits until 2030. Management at LIXTE and NOMAD frame this as a new category within the energy sector: not generation, not transmission, but rapid access to utility-grade power as a service. The company likens the shift to what cloud computing did for computing resources — turning a fixed, capital-heavy asset into something you can summon on demand.
The Permitting Moat Hiding in Plain Sight
The most underappreciated part of the story may be a regulatory quirk. Permanent, grid-scale battery storage projects in North America routinely face development timelines of two to five years or longer, tangled in a multi-agency gauntlet: land-use entitlements, zoning variances, environmental review under regimes like NEPA and CEQA, fire and safety review, and the interconnection queue itself. In a growing number of jurisdictions, local moratoria have stopped permanent battery projects outright. In New York State alone, by the company’s account, 108 local jurisdictions have enacted moratoria or bans on permanent battery storage development, with roughly a gigawatt of storage sidelined under such restrictions.
NOMAD’s pitch is that a mobile, transportable system sidesteps much of this. Because the platform is treated as equipment rather than permanent land use, it can, by the company’s description, avoid the entitlements and zoning variances that add a year or more to permanent projects, reduce or eliminate the environmental review that applies to fixed infrastructure, skip the multi-year interconnection queue, and operate in jurisdictions where permanent batteries are banned outright. Management argues this permitting and deployment advantage is one of the most underappreciated structural drivers behind the platform’s adoption — and a defining competitive feature of the deployable utility-grade category. For investors, it is the kind of structural edge that, if it holds up, is hard for competitors to replicate quickly.
A Sector Racing to Solve the Same Problem
NOMAD is far from alone in chasing the power-availability opportunity, and the breadth of public companies attacking it from different angles is itself evidence of how large the prize has become. Looking at a few of them helps frame where a deployable-BESS specialist fits — and the formidable company it would be keeping as a newly public infrastructure platform.
Fluence Energy, Inc. (NASDAQ: FLNC) is the clearest reference point for the battery-storage side of the trade. A global leader in grid-scale energy storage systems, Fluence has become a market favorite as AI-driven demand lifts storage names — the stock surged dramatically in 2026 on news of master supply agreements with hyperscalers and a record multibillion-dollar backlog, and it has been named an energy-storage partner on high-profile AI infrastructure projects. Fluence operates at a scale far beyond an emerging deployable-power company, but it validates the central thesis: utility-grade storage has become strategic infrastructure for the AI era.
Stem, Inc. (NYSE: STEM) approaches storage from the intelligence layer, providing AI-driven software that optimizes how batteries are dispatched and how they participate in energy markets. Stem is a useful comparison because NOMAD’s platform is not just hardware — the company emphasizes a 24/7 network operations center offering AI-assisted monitoring and fleet optimization. Stem illustrates the recurring-revenue, software-enabled dimension that storage companies increasingly layer on top of physical assets, the same direction NOMAD says it intends to grow.
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) represents the long-duration, domestically manufactured end of the storage spectrum, commercializing zinc-based battery systems built in the United States. As a higher-risk, higher-reward name tied to the same surge in demand for reliable stored power, Eos underscores how investors are funding a range of storage chemistries and form factors — and how a U.S.-made, safety-focused approach has become a selling point, echoing NOMAD’s emphasis on lithium iron phosphate chemistry and UL-validated safety systems.
Bloom Energy Corporation (NYSE: BE) attacks the availability problem from a different technology — on-site fuel cells that generate power directly at a data center or industrial site, bypassing the grid entirely. Bloom has become a leading name in the “bring your own power” movement, with multi-megawatt deployments at major data-center and enterprise sites. It is a complementary lens on the same thesis NOMAD is built around: when the grid cannot deliver fast enough, customers will pay for solutions that can. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in size, technology, and stage, and a newly transformed company like LIXTE would sit at the small, early end of that spectrum.
What the NOMAD Platform Actually Offers
Stripped of the macro framing, the operating business has concrete features. NOMAD says its platform is built on a UL 9540-validated architecture designed for utility-grade deployment, uses lithium iron phosphate chemistry for thermal stability and long life, and incorporates integrated fire detection and suppression. The company points to a first-mover position as the pioneer of the mobile, utility-grade 1 MW battery, an established customer base spanning investor-owned utilities, electric cooperatives, municipal utilities and industrial energy users, and a manufacturing roadmap it describes as scaling from roughly 2.5 gigawatts of production capacity in 2026 to about 3.5 gigawatts in 2027.
On the commercial side, management has cited revenue growth of approximately 175% year-over-year in 2025, with projections of roughly 135% growth in 2026 and in excess of 285% in 2027 — figures that are management estimates and projections rather than audited results, and that investors should treat accordingly. The company also reports that inbound opportunities represent about 75% of its sales activity and that it is tracking more than 30 active utility, infrastructure and strategic customer opportunities across North America, within an addressable market it pegs at roughly 3,200 electric utilities plus thousands of industrial users and a fast-growing base of AI infrastructure operators.
The Opportunity — and the Caveats
The bull case writes itself: a first-mover in a newly defined category, a structural permitting advantage, rapid revenue growth, and exposure to the single most powerful demand driver in the economy. “This transaction creates one of the first publicly traded companies singularly focused on solving one of the most significant constraints facing economic growth today — access to reliable electrical power,” said Geordan Pursglove, Chief Executive Officer of LIXTE. Stu Porter, a LIXTE director leading the strategic transformation and a veteran energy investor, framed the stakes even more broadly: “We believe access to power is becoming one of the defining economic challenges of the next decade.”
The caveats are equally real. This is a transformative acquisition that has not yet closed; the press release itself leaves transaction consideration, structure and timing to be finalized, and the deal remains subject to customary conditions. LIXTE is a small-cap company — until now a clinical-stage biotechnology business — undertaking a wholesale reinvention, and the growth and capacity figures are management projections for an emerging platform, not guarantees. Reinvention stories are exciting precisely because they are unproven. But the underlying current the company is trying to ride is not in doubt: across North America, the question is shifting from whether power can be generated to whether it can be delivered fast enough — and the companies positioned to close that gap are stepping into one of the largest infrastructure cycles in a generation.
CONTINUED … Learn more about LIXTE Biotechnology Holdings, Inc. at: https://lixte.com/
SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVES
Eagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.
Explore Eagle Eye free (for now) at https://Eagle-Eye.dev
SOURCES:
[1] LIXTE Biotechnology Holdings, Inc. — “LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems…” (company press release, June 2026; primary source for the acquisition, NOMAD platform, permitting advantages, growth figures, and management quotes):
https://ir.lixte.com/news-events/press-releases
[2] LIXTE Biotechnology Holdings, Inc. — SEC Form 8-K, “Strategic Transformation into AI Energy Infrastructure…” (June 1, 2026; NERC 224 GW peak-demand projection, Level 3 Alert, Stuart Porter board appointment):
https://www.sec.gov/Archives/edgar/data/0001335105/000149315226026544/ex99-1.htm
[3] Investing.com — “Lixte shifts from cancer drugs to AI energy infrastructure” (June 2026; LIXT share data, Denham Capital background, Nasdaq listing):
https://www.investing.com/news/company-news/lixte-shifts-from-cancer-drugs-to-ai-energy-infrastructure-93CH-4719357
[4] 24/7 Wall St. / Reuters — Fluence Energy backlog and hyperscaler supply agreements; AI-power storage sector context (May 2026):
https://247wallst.com/investing/2026/05/19/fluence-energy-just-ran-98-in-one-week-these-4-ai-power-stocks-under-20-have-not-had-their-moment-yet/
[5] InvestorPlace — AI energy-crunch sector overview (peer context: Bloom Energy, Fluence, Eos, Stem and the deployable/on-site power opportunity):
https://investorplace.com/hypergrowthinvesting/2025/12/the-coming-ai-energy-crunch-and-the-50-billion-opportunity-no-one-sees-yet/
DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed by Equity Insider on behalf of MIQ. MIQ has been paid a fee for LIXTE Biotechnology Holdings, Inc. advertising and digital media from Creative Direct Marketing Group (“CDMG”). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of LIXTE Biotechnology Holdings, Inc. but reserves the right to buy and sell shares of the company at any time without any further notice. There may be 3rd parties who may have shares of LIXTE Biotechnology Holdings, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of LIXTE Biotechnology Holdings, Inc. by CDMG; this is a digital media distribution.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. Statements regarding the proposed acquisition of NOMAD Transportable Power Systems, the intended corporate name change, projected revenue growth, production capacity, and market opportunity are forward-looking, reflect management’s current expectations, and are subject to risks and uncertainties; the transaction remains subject to closing conditions and may not be completed as described. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Bloom Energy stock is showing exceptional strength. What’s behind BE gains? What Is Driving Bloom Energy’s Recent Surge?On the policy side, sentiment has been tied to a "tariff-reset" framework, including certain steel and aluminum derivative tariffs cut to 15% from 25% for goods imported after 12:01 a.m. EST on June 8 through Dec. 31, 2027.
Bloom is also trading the nuance inside that tariff framework, including a 10% lane for capital equipment that is at least 85% U.S. "melted and poured," while parts of the 25% list expanded to include steel racks and aluminum lithographic plates after the stock’s massive run.
With the major indices modestly higher (Nasdaq up 0.22%, S&P 500 up 0.22%) and the Russell 2000 leading (up 1.00%), today's strength reads like a risk-on bid. That backdrop helps explain why Bloom is outperforming its sector by a wide margin even though Industrials is currently a mid-tier performer (ranked 7 of 11 sectors).
Bloom Energy’s Critical Price Levels To WatchThe longer-term trend remains bullish: the stock is up 1,094.38% over the past 12 months and is still well above its 200-day moving average ($148.23), with the golden cross from June 2025 keeping the bigger structure pointed higher. The near-term picture is more of a "digesting gains" setup, with shares trading 5.2% below the 20-day SMA ($278.91) but 7.3% above the 50-day SMA ($246.45).
Momentum looks more neutral than stretched right now, with RSI at 45.39—RSI measures how extended buying or selling pressure is, and this reading suggests the stock is cooling rather than overheated. From a trend-confirmation angle, MACD being below its signal line would align with that "cooling" message unless buyers re-accelerate.
Key Resistance: $303.00 — a round-number area near the upper end of the recent rebound zone where rallies can stall Key Support: $249.00 — a nearby pivot area sitting close to the 50-day moving average zone where dip-buyers often defend trend structure How Bloom Energy Generates Power and RevenueBloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation. Its Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications, with sales in the U.S. and internationally.
Bloom Energy’s Benzinga Edge Scorecard BreakdownBelow is the Benzinga Edge scorecard for Bloom Energy, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Bloom Energy’s Benzinga Edge signal reveals a classic High-Flyer setup—very strong Growth and Momentum paired with extremely weak Value. For longer-term holders, that mix can work in sustained uptrends, but it also raises the importance of respecting support levels when sentiment shifts.
Bloom Energy Stock Price Activity on FridayBE Stock Price Activity: Bloom Energy shares were up 5.15% at $261.70 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Investors interested in stocks from the Internet - Software sector have probably already heard of Magnite (MGNI - Free Report) and BlackLine (BL - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Magnite has a Zacks Rank of #2 (Buy), while BlackLine has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that MGNI likely has seen a stronger improvement to its earnings outlook than BL has recently. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
MGNI currently has a forward P/E ratio of 12.06, while BL has a forward P/E of 16.17. We also note that MGNI has a PEG ratio of 0.44. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. BL currently has a PEG ratio of 1.18.
Another notable valuation metric for MGNI is its P/B ratio of 1.98. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, BL has a P/B of 6.91.
These metrics, and several others, help MGNI earn a Value grade of B, while BL has been given a Value grade of D.
MGNI has seen stronger estimate revision activity and sports more attractive valuation metrics than BL, so it seems like value investors will conclude that MGNI is the superior option right now.
BlackLine (NASDAQ: BL - Get Free Report) has received a consensus recommendation of "Hold" from the fourteen brokerages that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating on the company. The average 12 month
Retirement comes 25 years after founding BlackLine Will remain on the Board of BlackLine LOS ANGELES, March 24, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) announced today that industry visionary Therese Tucker, the Company's founder and largest individual shareholder, will retire from full-time executive employment with the company effective June 2, 2026. Ms. Tucker, who owns approximately 8 percent of BlackLine's total outstanding shares, will remain actively engaged with the Company as a board member and significant shareholder.
LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) today announced Agentic Financial Operations, a new operating model aimed at solving the key challenge of trust and governance of AI for finance and accounting. The announcement, made at its annual BeyondTheBlack London conference, underscores BlackLine’s commitment to empowering finance leaders to confidently adopt and scale artificial intelligence. Agentic Financial Operations provides the essential control layer the Office of the CFO requires to harness AI safely, strategically, and at scale, ensuring BlackLine remains at the forefront of trusted AI.
BlackLine recognizes that fully realizing the transformative power of Agentic Financial Operations requires continuous, cutting-edge innovation. To accelerate this vision, the company is launching a dedicated AI Innovation Hub as part of a strategic investment in the future of trusted AI.
”CFOs need to leverage AI but remain personally liable for financial accuracy, so a ‘black box’ solution is not an option,” said Owen Ryan, CEO at BlackLine. “BlackLine’s Agentic Financial Operations solution gives leaders the confidence to scale by allowing them to independently validate AI outputs. Additionally, our strategic investment in a new AI Innovation Hub will be critical in continuing to build this trusted future, bringing together our partners, customers, and auditors to solve key AI challenges collaboratively.”
Powered by Agentic Financial Operations: The Solution for Trusted AI
Agentic Financial Operations is founded on the principle that as AI is deployed, trust becomes paramount. BlackLine’s model establishes a “glass box” architecture to orchestrate end-to-end financial processes - creating transparency across human and digital work and enabling finance to move from manual execution to continuous, insight-driven operations.
BlackLine’s approach is uniquely effective because it pairs a secure, auditable AI architecture with more than two decades of proprietary data, delivering the context and precision required for high-stakes financial operations. This gives CFOs the agency to act with confidence.
Customers are already recognizing the importance of this shift:
“If you look at where finance is heading over the next few years, it’s very clear that AI will fundamentally reshape how organizations operate. But it has to be AI built on strong accounting, logic, and compliance. We’ll be adopting more AI capabilities embedded within the BlackLine solution to reduce manual intervention, increase accuracy, and deliver more proactive insight into the close process.”
The Architecture for Agentic Financial Operations
BlackLine’s model, developed in collaboration with its partner ecosystem, is built on three core pillars that deliver speed and insight through a foundation of trust:
1. Governed Financial Data & Workflow Orchestration (Studio360™)
Studio360™ unifies financial operations with a high-quality data foundation from ledgers and systems, including new Snowflake and Workday connectors for expanded data access. This control plane orchestrates all workflow, data, and AI activity, offering on-demand insights through enhanced dashboards and visualizations.
2. An Agentic Intelligence Layer (Verity™ AI)
Verity™ delivers embedded, fully auditable AI capabilities built on BlackLine's extensive repository of accounting intelligence. It features a digital workforce of specialized agents designed to execute complex financial tasks with precision, deliver critical insights, and drive transformative process automation. Expanded capabilities include:
Verity Prepare: Automates end-to-end reconciliation with full traceability, reducing creation time by over 90% for early adoptersVerity Match: Uses AI to analyze historical patterns and improve match rates in complex reconciliations, leading to 80-90% match ratesVerity Collect and Remit: an agentic workforce that uses voice and digital agents that automate collections, summarize and prioritize customer interactions based on urgency and sentiment, and automates remittance processing with a ~90% straight-through processing rate, substantially reducing manual intervention
3. An Auditable and Certified System of Record for AI
BlackLine's AI is grounded in deep accounting intelligence and operational data, a proprietary "ground truth" accumulated from learning from billions of transactions and thousands of customers. With a robust governance framework built into its architecture, BlackLine ensures every AI-driven action is not only accurate but also fully explainable and auditable. This commitment delivers trusted AI, providing finance leaders with confidence and control.
“BlackLine's strategic investments underscore a fundamental truth in the AI era: the value of sophisticated AI models is fully realized only when paired with the robust control layer that governs them,” said Jeremy Ung, Chief Technology Officer at BlackLine. “These innovations solidify BlackLine's commitment to this principle. They empower the company to constantly evolve Agentic Financial Operations, building a system where every action is traceable, auditable, and aligned to financial controls, giving finance teams the ultimate confidence to scale AI.”
Fueling AI Innovation with Strategic Investments
BlackLine is creating an AI Innovation Hub in New York to accelerate the future of trusted AI for finance and accounting teams. This hub will be designed as a magnet for world-class talent, with a dedicated team of leading AI researchers and product development engineers collaborating with BlackLine’s ecosystem of system integrators, ERP vendors, business process outsourcing firms, auditors, and customers. This ecosystem will significantly accelerate BlackLine's Agentic Financial Operations capabilities, building on Verity and combining capabilities from its recent WiseLayer acquisition. Innovation emerging from this hub will actively power and accelerate Agentic Financial Operations, ensuring that advancements in automation and intelligence are intrinsically aligned with the stringent control, auditability, and trust requirements vital for modern finance.
About BlackLine
BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations. Built on the Studio360 platform, BlackLine unifies data, streamlines processes, and delivers real-time insights through automation and intelligence powered by Verity - a comprehensive suite of embedded, auditable AI capabilities that provides finance and accounting teams with a new digital workforce.
With a proven, collaborative approach and a track record of innovation supported by industry-leading R&D investment and world-class security practices, more than 4,300 customers across multiple industries partner with BlackLine to lead their organizations into the future. For more information, visit blackline.com.
Safe Harbor
This document contains forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of BlackLine, Inc. ("BlackLine" or the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, introduction of new solutions or products, expansion into new markets, regulatory compliance, plans for growth and future operations, technological capabilities, and strategic relationships, as well as assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expect," "plan," anticipate," "believe," "estimate," "predict," "intend," "potential," "would," "continue," "ongoing" or the negative of these terms or other comparable terminology. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.
Forward-looking statements are based on information available at the time those statements are made and/or management's good faith beliefs and assumptions as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. These risks and uncertainties are described in greater detail under the heading "Risk Factors" in the filings we make with the Securities and Exchange Commission ("SEC") from time to time, which are available on our website at http://investors.BlackLine.com and on the SEC's website at www.sec.gov. Except as required by law, BlackLine does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
In addition to U.S. GAAP financials, this document includes certain non-GAAP financial measures, including non-GAAP revenue, gross profit, gross margin, free cash flow, sales and marketing expense, research and development expense, general and administrative expense, loss from operations and operating margin (loss). These non-GAAP measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with U.S. GAAP. The non-GAAP financial measures we use may differ from the non-GAAP financial measures used by other companies.
LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) announced today that it will release financial results for the first quarter ended March 31, 2026 after market close on Tuesday, May 5, 2026 followed by a conference call hosted by management at 2:00 p.m. PT / 5:00 p.m. ET. A live webcast and replay will be accessible on BlackLine’s investor relations website at https://investors.blackline.com. To access the conference call by phone, please register here, and dial-in details will be provided. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
About BlackLine
BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations. Built on the Studio360 platform, BlackLine unifies data, streamlines processes, and delivers real-time insights through automation and intelligence powered by Verity - a comprehensive suite of embedded, auditable AI capabilities that provides finance and accounting teams with a new digital workforce.
With a proven, collaborative approach and a track record of innovation supported by industry-leading R&D investment and world-class security practices, more than 4,300 customers across multiple industries partner with BlackLine to lead their organizations into the future.
On April 24, 2026, BlackLine Inc BL shares rose 4.3% to $30.64. Despite today's positive movement, the stock has faced a challenging year, declining 44.6% year-to-date and 34.6% over the past year, with a 52-week trading range between $28.78 and $59.57.
GF Value™ verdict: Current price of $30.64 is 52.2% below the GF Value™ of $64.07.GF Score™: 70/100, indicating an above-average potential for long-term returns.Most notable signal: No insider transactions in the last 3 months. Is BL Overvalued or Undervalued? Based on the current price of $30.64 compared to the GF Value™ of $64.07, BlackLine Inc appears to be significantly undervalued, with a margin of safety of 52.2%. This suggests that the market may not fully recognize the company's potential growth and profitability. However, it is important to note that the GF Valuation label indicates a possible value trap, which suggests caution due to potential risks associated with the stock's performance. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
The considerable difference between the current market price and the GF Value™ presents an opportunity for investors who believe in the company's future growth prospects. Nevertheless, investors should consider the underlying financial metrics and market conditions before making any decisions.
How Does BL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 76.6x 56.4x Forward P/E 12.8x N/A Currently, BlackLine Inc's P/E (TTM) is 76.6x, which is 36% above its 5-year median P/E of 56.4x. The forward P/E of 12.8x suggests that the market expects significant earnings growth in the future. This analysis indicates that the stock is trading above its historical valuation, which is inconsistent with the GF Value™ verdict of undervaluation, highlighting a potential disconnect between current market sentiment and intrinsic value.
What Does BL's GF Score™ Tell Us? Metric Rating GF Score™ 70/100 Financial Strength 5/10 Profitability 4/10 Growth 8/10 Valuation 2/10 Momentum 4/10 The GF Score™ for BlackLine Inc is 70/100, indicating a generally above-average potential for long-term returns. The strongest area is growth, with a ranking of 8/10, suggesting robust growth prospects. However, the valuation rank at 2/10 reflects concerns about the stock's current price relative to its intrinsic value. Financial strength and profitability are also moderate, with scores of 5/10 and 4/10, respectively, indicating some vulnerabilities that investors should consider.
What Are Insiders Doing with BL Stock? There have been no insider transactions in the last three months for BlackLine Inc. This lack of insider activity can suggest that company executives do not view the current stock price as an attractive buying opportunity, or it may imply a wait-and-see approach regarding the company's future performance. Investors often look to insider transactions as signals of confidence in the company's prospects, so this absence could be interpreted as a cautionary indicator.
What This Means for Investors BlackLine Inc is currently undervalued based on the GF Value™ assessment, with a significant margin of safety. However, potential investors should be aware of the risks indicated by the GF Valuation label, which suggests the possibility of a value trap. It is crucial to consider the overall financial health and market conditions surrounding the company.
For the complete analysis, visit the BlackLine Inc BL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is BL's GF Score™?
BL's GF Score™ is 70/100, indicating that it has above-average potential for long-term returns based on various financial metrics.
Is BL overvalued or undervalued?
BL is currently undervalued, with a GF Value™ of $64.07 compared to its market price of $30.64, suggesting significant upside potential.
What is BL's P/E ratio?
BL's P/E ratio (TTM) is 76.6x, which is significantly higher than its 5-year median P/E of 56.4x, indicating that the stock is trading above its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
On April 28, 2026, BlackLine Inc BL shares rose 3.4% today, closing at $31.68. Despite this daily gain, the stock has experienced significant declines over the past year, with a 52-week trading range between $28.78 and $59.57.
GF Value™ verdict: Current price of $31.68 is 50.6% undervalued compared to GF Value™ of $64.07.GF Score™ is 70/100, indicating an above-average potential for long-term returns.Notable signal: BlackLine's financial strength is rated 5/10. Is BL Overvalued or Undervalued? BlackLine Inc's current share price of $31.68 is significantly lower than the GF Value™ estimate of $64.07, suggesting that the stock is undervalued by approximately 50.6%. This margin of safety indicates a potential opportunity for value-focused investors. However, the GF Valuation label warns that this could be a possible value trap, advising caution before making any investment decisions. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
The disparity between the current market price and the estimated intrinsic value raises questions about the sustainability of BlackLine's growth and profitability. While the undervaluation presents an attractive entry point, investors must consider the company's financial health and market conditions that may affect future performance.
How Does BL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 79.2x 56.5x (5-Year Median) Forward P/E 13.2x - BlackLine's current P/E (TTM) of 79.2x is significantly above its 5-year median of 56.5x, indicating that the stock is trading at a premium compared to its historical valuation. This analysis aligns with the GF Value™ verdict, suggesting that while the stock may appear undervalued in terms of GF Value™, the high P/E ratio signals caution regarding its valuation metrics.
What Does BL's GF Score™ Tell Us? Metric Rating GF Score™ 70/100 Financial Strength 5/10 Profitability 4/10 Growth 8/10 Valuation 2/10 Momentum 4/10 The GF Score™ of 70/100 indicates that BlackLine Inc has above-average potential for long-term returns based on its financial metrics. The strongest area is its growth rank of 8/10, reflecting robust growth potential. However, the weakest area is the valuation rank of 2/10, suggesting that the stock may be overvalued based on its current metrics, which could pose risks for potential investors.
What Are Insiders Doing with BL Stock? There have been no insider transactions in the last three months for BlackLine Inc. This lack of activity suggests that insiders may not see immediate value in the current pricing or may be waiting for more favorable conditions before making any moves. The absence of insider buying could indicate a lack of confidence in the stock's short-term prospects.
What This Means for Investors Based on the GF Value™ assessment, BlackLine Inc is currently undervalued. However, prospective investors should consider the risks associated with the high current P/E ratio and the potential for a value trap as indicated by the GF Valuation label. Caution is advised when evaluating the stock's future performance and market conditions.
For the complete analysis, visit the BlackLine Inc BL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is BL's GF Score™?
BlackLine Inc's GF Score™ is 70/100, indicating an above-average potential for long-term returns based on its financial health and performance metrics.
Is BL overvalued or undervalued?
According to GF Value™, BlackLine Inc is undervalued with a current price of $31.68 compared to its fair value estimate of $64.07, suggesting a significant opportunity.
What is BL's P/E ratio?
BlackLine's P/E ratio is 79.2x, which is significantly higher than its 5-year median of 56.5x, indicating that the stock is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Investors with an interest in Internet - Software stocks have likely encountered both BlackLine (BL - Free Report) and Autodesk (ADSK - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Both BlackLine and Autodesk have a Zacks Rank of #2 (Buy) right now. This means that both companies have witnessed positive earnings estimate revisions, so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
BL currently has a forward P/E ratio of 13.26, while ADSK has a forward P/E of 18.97. We also note that BL has a PEG ratio of 0.97. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ADSK currently has a PEG ratio of 1.17.
Another notable valuation metric for BL is its P/B ratio of 5.67. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ADSK has a P/B of 16.27.
These metrics, and several others, help BL earn a Value grade of B, while ADSK has been given a Value grade of C.
Both BL and ADSK are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that BL is the superior value option right now.
LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL), today announced financial results for the first quarter ended March 31, 2026.
“BlackLine delivered a solid first quarter with accelerating revenue growth, operating leverage, and momentum from our platform strategy,” said Owen Ryan, CEO of BlackLine. “We are defining the future of the financial close with Agentic Financial Operations, turning our vision for trusted, auditable AI into commercial reality. The growing adoption of our Verity AI capabilities and Studio360 demonstrate that CFOs view BlackLine as the essential governance layer for the AI era. Driven by strong execution and a growing pipeline, we are raising our full-year outlook while continuing to deliver durable, profitable growth.”
First Quarter 2026 Financial Highlights
Total GAAP revenues of $183.2 million, an increase of 9.7% compared to the first quarter of 2025.GAAP operating margin of 3.4%, compared to 2.1% in the first quarter of 2025.Non-GAAP operating margin of 21.6%, compared to 20.9% in the first quarter of 2025.GAAP net income attributable to BlackLine of $8.1 million, or $0.13 per diluted share compared to GAAP net income attributable to BlackLine of $6.1 million, or $0.10 per diluted share in the first quarter of 2025.Non-GAAP net income attributable to BlackLine of $39.6 million, or $0.56 per diluted share compared to non-GAAP net income attributable to BlackLine of $36.3 million, or $0.49 per diluted share in the first quarter of 2025.Billings of $173.7 million, an increase of 9.2% compared to the first quarter of 2025.Remaining performance obligation of $1.1 billion, an increase of 17.9% compared to the first quarter of 2025.Operating cash flow of $46.3 million, compared to $46.7 million in the first quarter of 2025.Free cash flow of $35.8 million, compared to $32.6 million in the first quarter of 2025.Repurchased approximately 1.2 million shares of common stock for $47.1 million as part of our share repurchase program under which approximately $217.4 million of buyback capacity remained at March 31, 2026. First Quarter Key Metrics and Recent Business Highlights
BlackLine had a total of 4,301 customers at March 31, 2026.Platform pricing Annual Recurring Revenue (ARR) as a percentage of eligible ARR, which excludes Solex and public sector ARR, was 13% at March 31, 2026.Achieved a dollar-based net revenue retention rate of 105% at March 31, 2026.Unveiled Agentic Financial Operations, a new operating model to solve key challenges of trust and governance of AI for finance and accounting.Announced the creation of BlackLine’s first AI Innovation Hub located in New York City.Hosted BeyondTheBlack London, BlackLine’s European-focused customer conference.Hosted a virtual AI investor session, showcasing the Company’s AI innovation.Announced the retirement of BlackLine’s founder, Therese Tucker. The financial results included in this press release are preliminary and subject to final review. Financial results will not be final until BlackLine files its Quarterly Report on Form 10-Q for the period. Information about BlackLine’s use of non-GAAP financial measures is provided below under “Use of Non-GAAP Financial Measures.”
Financial Outlook
Second Quarter 2026
Total GAAP revenue is expected to be in the range of $186 million to $188 million.Non-GAAP operating margin is expected to be in the range of 21.5% to 22.5%.Non-GAAP net income attributable to BlackLine is expected to be in the range of $40 million to $42 million, or $0.57 to $0.59 per share on 73.3 million diluted weighted average shares outstanding. Full Year 2026
Total GAAP revenue is expected to be in the range of $765 million to $769 million.Non-GAAP operating margin is expected to be in the range of 24.0% to 24.5%.Non-GAAP net income attributable to BlackLine is expected to be in the range of $174 million to $182 million, or $2.42 to $2.53 per share on 74.4 million diluted weighted average shares outstanding. Guidance for non-GAAP operating margin, non-GAAP net income attributable to BlackLine, and non-GAAP net income per share attributable to BlackLine excludes specified items from the corresponding GAAP financial measures as outlined below under “Use of Non-GAAP Financial Measures” and as detailed in the reconciliations of non-GAAP measures for historical periods. Reconciliations of non-GAAP operating margin, non-GAAP net income attributable to BlackLine, and non-GAAP net income per share attributable to BlackLine guidance to the most directly comparable U.S. GAAP measures are not available on a forward-looking basis without unreasonable efforts due to the unpredictability and complexity of the charges excluded from these non-GAAP financial measures. The Company expects the variability of the above items could have a significant, and potentially unpredictable, impact on its future GAAP operating margin, net income attributable to BlackLine, and net income per share attributable to BlackLine.
Quarterly Conference Call
BlackLine will hold a conference call to discuss its first quarter results at 2:00 p.m. Pacific time on Tuesday, May 5, 2026. A live audio webcast will be accessible on BlackLine’s investor relations website at https://investors.blackline.com. Participants can preregister for the conference call. A replay of the webcast will be available at https://investors.blackline.com for 12 months. BlackLine has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About BlackLine
BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations. Built on the Studio360 platform, BlackLine unifies data, streamlines processes, and delivers real-time insights through automation and intelligence powered by Verity - a comprehensive suite of embedded, auditable AI capabilities that provides finance and accounting teams with a new digital workforce.
With a proven, collaborative approach and a track record of innovation supported by industry-leading R&D investment and world-class security practices, more than 4,300 customers across multiple industries partner with BlackLine to lead their organizations into the future.
For more information, please visit blackline.com.
Forward-looking Statements
This release and the conference call referenced above contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “potential,” “would,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology. Forward-looking statements in this release and quarterly conference call include, but are not limited to, statements regarding BlackLine’s future financial and operational performance, including, without limitation, GAAP and non-GAAP guidance for the second quarter and full year of 2026, the impact of progress against certain key initiatives, our expectations for our business, including the demand environment, BlackLine’s addressable market, market position and pipeline, our international growth, and our relationships with our customers and partners, including opportunities to expand those relationships.
Any forward-looking statements contained in this press release or the quarterly conference call are based upon BlackLine’s historical performance and its current plans, estimates and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good-faith beliefs and assumptions as of that time with respect to future events, and are subject to risks and uncertainties. If any of these risks or uncertainties materialize or if any assumptions prove incorrect, actual performance or results may differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to attract new customers and expand sales to existing customers; the extent to which customers renew their subscription agreements or increase the number of users; the impact of current and future economic uncertainty and other unfavorable conditions in the Company's industry or the global economy; the Company’s ability to manage growth and scale effectively, including entry into new geographies; the Company’s ability to provide successful enhancements, new features and modifications to its software solutions; the Company’s ability to develop new products and software solutions and the success of any new product and service introductions; the Company's ability to effectively incorporate artificial intelligence and machine learning technologies (AI/ML) into its platform and business and the potential reputational harm or legal liability that may result from the use of AI/ML solutions and features; the success of the Company’s strategic relationships with technology vendors and business process outsourcers, channel partners and alliance partners; any breaches of the Company’s security measures; a disruption in the Company’s hosting network infrastructure; costs and reputational harm that could result from defects in the Company’s solutions; the loss of any key employees; continued strong demand for the Company’s software in the United States, Europe, Asia Pacific, and Latin America; the Company’s ability to compete as the financial close management provider for organizations; the timing and success of solutions offered by competitors including competitors' ability to incorporate AI/ML into products and offerings more quickly or successfully; changes in the proportion of the Company’s customer base that is comprised of enterprise or mid-sized organizations; the Company’s ability to expand and effectively manage its sales teams and their performance and productivity; fluctuations in our financial results due to long and increasingly variable sales cycles; failure to protect the Company’s intellectual property; the Company’s ability to integrate acquired businesses and technologies successfully or achieve the expected benefits of such transactions; unpredictable and uncertain macro and regional economic conditions; seasonality; changes in current tax or accounting rules; cyber attacks and the risk that the Company’s security measures may not be sufficient to secure its customer or confidential data adequately; acts of terrorism or other vandalism, war, or natural disasters including the effects of climate change; the impact of any determination of deficiencies or weaknesses in our internal controls and processes; and other risks and uncertainties described in the other filings we make with the Securities and Exchange Commission from time to time, including the risks described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 26, 2026. Additional information will also be set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Forward-looking statements should not be read as a guarantee of future performance or results, and you should not place undue reliance on such statements. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. All of the information in this press release is subject to completion of our quarterly review process.
Use of Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, BlackLine has provided in this release and the quarterly conference call held on May 5, 2026, certain financial measures that have not been prepared in accordance with GAAP defined as “non-GAAP financial measures,” which include (i) non-GAAP gross profit and non-GAAP gross margin, (ii) non-GAAP operating expenses, (iii) non-GAAP operating income and non-GAAP operating margin, (iv) non-GAAP net income attributable to BlackLine, Inc., (v) diluted non-GAAP net income per share attributable to BlackLine, Inc., and (vi) free cash flow.
BlackLine’s management uses these non-GAAP financial measures internally in analyzing its financial results and believes they are useful to investors, as a supplement to the corresponding GAAP measures, in evaluating BlackLine’s ongoing operational performance and trends and in comparing its financial measures with other companies in the same industry, many of which present similar non-GAAP financial measures to help investors understand the operational performance of their businesses. However, it is important to note that the particular items BlackLine excludes from, or includes in, its non-GAAP financial measures may differ from the items excluded from, or included in, similar non-GAAP financial measures used by other companies in the same industry. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures has been provided in the tables included as part of this press release.
Non-GAAP Gross Profit and Non-GAAP Gross Margin. Non-GAAP gross profit is defined as GAAP revenues less GAAP cost of revenue adjusted for amortization of acquired developed technology, stock-based compensation, and transaction-related costs (including, but not limited to, accounting, legal, and advisory fees related to the transaction, as well as transaction-related retention bonuses). Non-GAAP gross margin is defined as non-GAAP gross profit divided by GAAP revenues. BlackLine believes that presenting non-GAAP gross profit and non-GAAP gross margin is useful to investors as it eliminates the impact of certain non-cash expenses and allows a direct comparison of gross profit between periods.
Non-GAAP Operating Expenses. Non-GAAP operating expenses include (a) non-GAAP sales and marketing expense, (b) non-GAAP research and development expense, and (c) non-GAAP general and administrative expense. Non-GAAP sales and marketing expense is defined as GAAP sales and marketing expense adjusted for amortization of intangible assets, stock-based compensation, and transaction-related costs. Non-GAAP research and development expense is defined as GAAP research and development expense adjusted for stock-based compensation and transaction-related costs. Non-GAAP general and administrative expense is defined as GAAP general and administrative expense adjusted for amortization of intangible assets, stock-based compensation, change in fair value of contingent consideration, transaction-related costs, restructuring costs, and legal settlement gains or costs. BlackLine believes that presenting each of the non-GAAP operating expenses is useful to investors as it eliminates the impact of certain cash and non-cash expenses and allows a direct comparison of operating expenses between periods.
Non-GAAP Income from Operations and Non-GAAP Operating Margin. Non-GAAP income from operations is defined as GAAP income from operations adjusted for amortization of intangible assets, stock-based compensation, change in fair value of contingent consideration, transaction-related costs, restructuring costs, and legal settlement gains or costs. Non-GAAP operating margin is defined as non-GAAP income from operations divided by GAAP revenues. BlackLine believes that presenting non-GAAP income from operations and non-GAAP operating margin is useful to investors as it eliminates the impact of items that have been impacted by the Company’s acquisitions and other related costs in order to allow a direct comparison of income from operations between all periods presented.
Non-GAAP Net Income Attributable to BlackLine and Diluted Non-GAAP Net Income Per Share Attributable to BlackLine, Inc. Non-GAAP net income attributable to BlackLine is defined as GAAP net income attributable to BlackLine adjusted for the income tax effects of acquisitions, stock-based compensation shortfalls and windfalls, and the discrete tax impact of other non-GAAP adjustments, amortization of intangible assets, stock-based compensation, amortization of debt issuance costs from our convertible senior notes, change in fair value of contingent consideration, transaction-related costs, restructuring costs, legal settlement gains or costs, adjustment to the redeemable non-controlling interest to the redemption amount, and gain on extinguishment of convertible senior notes. Diluted non-GAAP net income per share attributable to BlackLine, Inc. includes the adjustment for shares resulting from the elimination of stock-based compensation. BlackLine believes that presenting non-GAAP net income attributable to BlackLine is useful to investors as it eliminates the impact of items that have been impacted by the Company’s acquisitions and other related costs to allow a direct comparison of net income between all periods presented.
Free Cash Flow. Free cash flow is defined as cash flows provided by operating activities less cash flows used to purchase property and equipment, financed and otherwise, capitalized software development, and intangible assets. BlackLine believes that presenting free cash flow is useful to investors as it provides a measure of the Company’s liquidity used by management to evaluate the amount of cash generated by the Company’s business including the impact of purchases of property and equipment and cost of capitalized software development.
Use of Operating Metrics
BlackLine has provided in this release and the quarterly conference call held on May 5, 2026 certain operating metrics, including (i) number of customers, (ii) Platform pricing ARR as a percentage of eligible ARR, and (iii) dollar-based net revenue retention rate, which BlackLine uses to evaluate its business, measure its performance, identify trends affecting its business, formulate financial projections and make strategic decisions.
Number of Customers. A customer is defined as a company that contributes to our subscription and support revenue as of the measurement date. In situations where an organization has multiple subsidiaries or divisions, each entity that is invoiced as a separate entity is treated as a separate customer. In an instance where an existing customer requests its invoice be divided for the sole purpose of restructuring its internal billing arrangement without any incremental increase in revenue, such customer continues to be treated as a single customer. BlackLine believes that its ability to expand its customer base is an indicator of the Company’s market penetration and the growth of its business.
Platform Pricing ARR as a Percentage of Eligible ARR. Platform pricing ARR as a percentage of eligible ARR is calculated as platform annual recurring revenue divided by our eligible annual recurring revenue. We define eligible ARR as total annual recurring revenue, excluding revenue from SAP solutions-extensions (“SolEx”) and the public sector.
Dollar-based Net Revenue Retention Rate. Dollar-based net revenue retention rate is calculated as the implied monthly subscription and support revenue at the end of a period for the base set of customers from which the Company generated subscription revenue in the year prior to the calculation, divided by the implied monthly subscription and support revenue one year prior to the date of calculation for that same customer base. This calculation does not reflect implied monthly subscription and support revenue for new customers added during the one-year period but does include the effect of customers who terminated during the period. Implied monthly subscription and support revenue is defined as the total amount of minimum subscription and support revenue contractually committed to, under each of BlackLine’s customer agreements over the entire term of the agreement, divided by the number of months in the term of the agreement. BlackLine believes that dollar-based net revenue retention rate is an important metric to measure the long-term value of customer agreements and the Company’s ability to retain and grow its relationships with existing customers over time.
BlackLine, Inc.Condensed Consolidated Balance Sheets(in thousands)(unaudited) March 31, 2026 December 31, 2025ASSETSCurrent assets: Cash and cash equivalents$242,041 $390,034 Marketable securities 283,030 388,178 Accounts receivable, net of allowances 174,890 218,100 Prepaid expenses and other current assets 32,141 28,897 Total current assets 732,102 1,025,209 Capitalized software development costs, net 50,689 49,494 Property and equipment, net 12,957 13,255 Intangible assets, net 45,569 49,352 Goodwill 465,715 465,804 Operating lease right-of-use assets 19,531 22,756 Deferred tax assets, net 37,739 39,341 Other assets 91,216 94,308 Total assets$1,455,518 $1,759,519 LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, AND STOCKHOLDERS' EQUITYCurrent liabilities: Accounts payable$5,846 $15,523 Accrued expenses and other current liabilities 59,421 76,790 Deferred revenue, current 359,598 368,593 Finance lease liabilities, current 13 12 Operating lease liabilities, current 4,856 4,436 Convertible senior notes, net, current — 230,023 Total current liabilities 429,734 695,377 Finance lease liabilities, noncurrent 37 40 Operating lease liabilities, noncurrent 15,737 19,850 Convertible senior notes, net, noncurrent 666,678 666,046 Deferred tax liabilities, net 4,585 5,244 Deferred revenue, noncurrent 447 922 Other long-term liabilities 779 593 Total liabilities 1,117,997 1,388,072 Commitments and contingencies Redeemable non-controlling interest 31,571 39,121 Stockholders' equity: Common stock 592 599 Additional paid-in capital 327,307 356,841 Accumulated other comprehensive loss (628) (296)Accumulated deficit (21,321) (24,818)Total stockholders' equity 305,950 332,326 Total liabilities, redeemable non-controlling interest, and stockholders' equity$1,455,518 $1,759,519 BlackLine, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data)(unaudited) Quarter Ended March 31, 2026 2025 Revenues Subscription and support$173,714 $158,462 Professional services 9,441 8,469 Total revenues 183,155 166,931 Cost of revenues Subscription and support 36,436 34,130 Professional services 7,569 6,794 Total cost of revenues 44,005 40,924 Gross profit 139,150 126,007 Operating expenses Sales and marketing 67,421 63,063 Research and development 30,560 25,725 General and administrative 33,241 28,345 Restructuring costs 1,693 5,299 Total operating expenses 132,915 122,432 Income from operations 6,235 3,575 Other income (expense) Interest income 6,058 8,892 Interest expense (2,494) (2,522)Other income, net 3,564 6,370 Income before income taxes 9,799 9,945 Provision for income taxes 5,908 4,671 Net income 3,891 5,274 Net income attributable to redeemable non-controlling interest 394 397 Adjustment attributable to redeemable non-controlling interest (4,629) (1,178)Net income attributable to BlackLine, Inc.$8,126 $6,055 Basic net income per share attributable to BlackLine, Inc.$0.14 $0.10 Shares used to calculate basic net income per share 59,439 62,822 Diluted net income per share attributable to BlackLine, Inc.$0.13 $0.10 Shares used to calculate diluted net income per share 69,835 64,839 BlackLine, Inc.Calculation of Diluted Net Income Per Share(in thousands, except per share data)(unaudited) Quarter Ended March 31, 2026 2025Diluted Net Income Per Share Numerator: Net income attributable to BlackLine, Inc.$8,126 $6,055Interest expense, net of taxes 1,041 125Net income attributable to BlackLine, Inc. for diluted calculation$9,167 $6,180Denominator: Weighted average shares 59,439 62,822Dilutive effect of securities 538 632Dilutive effect of convertible senior notes 9,858 1,385Shares used to calculate diluted net income per share 69,835 64,839Diluted net income per share attributable to BlackLine, Inc.$0.13 $0.10 BlackLine, Inc.Condensed Consolidated Statements of Cash Flows(in thousands)(unaudited) Quarter Ended March 31, 2026 2025 Cash flows from operating activities Net income attributable to BlackLine, Inc.$8,126 $6,055 Net income and adjustment attributable to redeemable non-controlling interest (4,235) (781)Net income 3,891 5,274 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 12,166 11,498 Amortization of debt issuance costs 805 834 Stock-based compensation 23,741 18,574 Noncash lease expense 1,545 1,397 Accretion of purchase discounts on marketable securities, net (2,544) (1,968)Net foreign currency (gains) losses 122 (227)Deferred income taxes 979 (1,313)Provision for (benefit from) credit losses (3) 56 Changes in operating assets and liabilities: Accounts receivable 41,862 32,737 Prepaid expenses and other current assets (3,308) (1,878)Other assets 3,106 (517)Accounts payable (7,716) (3,590)Accrued expenses and other current liabilities (17,477) (6,631)Deferred revenue (9,455) (8,024)Operating lease liabilities (1,628) (1,510)Lease incentive receipts — 30 Other long-term liabilities 210 2,000 Net cash provided by operating activities 46,296 46,742 Cash flows from investing activities Purchases of marketable securities (68,490) (384,923)Proceeds from maturities of marketable securities 174,272 — Proceeds from sales of marketable securities 1,626 — Capitalized software development costs (8,411) (8,167)Purchases of property and equipment (2,117) (5,951)Net cash provided by (used in) investing activities 96,880 (399,041)Cash flows from financing activities Purchase of additional redeemable non-controlling interest (3,291) — Repayment of convertible senior notes (230,196) — Principal payments under finance lease obligations (3) (57)Repurchases of common stock (45,990) (45,451)Proceeds from exercises of stock options 59 2,136 Proceeds from exercises of stock options - redeemable non-controlling interest 152 — Acquisition of common stock for tax withholding obligations (11,763) (10,939)Net cash used in financing activities (291,032) (54,311)Effect of foreign currency exchange rate changes on cash, cash equivalents, and restricted cash (137) 240 Net decrease in cash, cash equivalents, and restricted cash (147,993) (406,370)Cash, cash equivalents, and restricted cash, beginning of period 390,220 886,147 Cash, cash equivalents, and restricted cash, end of period$242,227 $479,777 Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets: Cash and cash equivalents at end of period$242,041 $479,536 Restricted cash included within prepaid expenses and other current assets at end of period 186 — Restricted cash included within other assets at end of period — 241 Total cash, cash equivalents, and restricted cash at end of period shown in the condensed consolidated statements of cash flows$242,227 $479,777 BlackLine, Inc.Reconciliations of Non-GAAP Financial Measures(in thousands, except percentages and per share data)(unaudited) Quarter Ended March 31, 2026 2025 Non-GAAP Gross Profit: Gross profit$139,150 $126,007 Amortization of acquired developed technology 3,522 3,173 Stock-based compensation 4,281 3,646 Transaction-related costs — 8 Total non-GAAP gross profit$146,953 $132,834 Gross margin 76.0% 75.5%Non-GAAP gross margin 80.2% 79.6% Non-GAAP Operating Income: Operating income$6,235 $3,575 Amortization of intangible assets 3,783 3,650 Stock-based compensation 24,785 19,419 Transaction-related costs 2,923 3,010 Restructuring and legal settlement costs 1,878 5,299 Total non-GAAP operating income$39,604 $34,953 GAAP operating margin 3.4% 2.1%Non-GAAP operating margin 21.6% 20.9% Non-GAAP Net Income Attributable to BlackLine, Inc.: Net income attributable to BlackLine, Inc.$8,126 $6,055 Provision for (benefit from) income taxes 1,935 (654)Amortization of intangible assets 3,783 3,650 Stock-based compensation 24,785 19,308 Amortization of debt issuance costs 805 834 Transaction-related costs 2,923 3,010 Restructuring and legal settlement costs 1,878 5,299 Adjustment to redeemable non-controlling interest (4,629) (1,178)Total non-GAAP net income attributable to BlackLine, Inc.$39,606 $36,324 Basic Non-GAAP Net Income Per Share Attributable to BlackLine, Inc.: Basic non-GAAP net income per share attributable to BlackLine, Inc.$0.67 $0.58 Shares used to calculate basic non-GAAP net income per share 59,439 62,822 Diluted Non-GAAP Net Income Per Share Attributable to BlackLine, Inc. Numerator: Non-GAAP net income attributable to BlackLine, Inc.$39,606 $36,324 Interest expense, net of taxes 1,535 1,472 Non-GAAP net income attributable to BlackLine, Inc. for diluted calculation$41,141 $37,796 Denominator: Weighted average shares 59,439 62,822 Dilutive effect of securities 3,733 2,985 Dilutive effect of convertible senior notes 9,858 11,243 Shares used to calculate diluted non-GAAP net income per share 73,030 77,050 Diluted non-GAAP net income per share attributable to BlackLine, Inc.$0.56 $0.49 Non-GAAP Sales and Marketing Expense: Sales and marketing expense$67,421 $63,063 Amortization of intangible assets (182) (398)Stock-based compensation (6,947) (6,044)Transaction-related costs — (10)Total non-GAAP sales and marketing expense$60,292 $56,611 Non-GAAP Research and Development Expense: Research and development expense$30,560 $25,725 Stock-based compensation (4,732) (3,350)Transaction-related costs — (21)Total non-GAAP research and development expense$25,828 $22,354 Non-GAAP General and Administrative Expense: General and administrative expense$33,241 $28,345 Amortization of intangible assets (79) (79)Stock-based compensation (8,825) (6,379)Transaction-related costs (2,923) (2,971)Restructuring and legal settlement costs (185) — Total non-GAAP general and administrative expense$21,229 $18,916 Total Non-GAAP Operating Expenses$107,349 $97,881 Free Cash Flow Net cash provided by operating activities$46,296 $46,742 Capitalized software development costs (8,411) (8,167)Purchases of property and equipment (2,117) (5,951)Free cash flow$35,768 $32,624
For the quarter ended March 2026, BlackLine (BL - Free Report) reported revenue of $183.16 million, up 9.7% over the same period last year. EPS came in at $0.56, compared to $0.58 in the year-ago quarter.
The reported revenue represents a surprise of +1.25% over the Zacks Consensus Estimate of $180.9 million. With the consensus EPS estimate being $0.45, the EPS surprise was +24.92%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how BlackLine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Billings: $173.7 million versus $175.39 million estimated by three analysts on average.Total customers: 4,301 compared to the 4,381 average estimate based on two analysts.Retention Rate: 105% versus 104.5% estimated by two analysts on average.Revenues- Professional services: $9.44 million compared to the $9.06 million average estimate based on three analysts. The reported number represents a change of +11.5% year over year.Revenues- Subscription and support: $173.71 million versus the three-analyst average estimate of $171.84 million. The reported number represents a year-over-year change of +9.6%.Gross profit- Professional services: $1.87 million compared to the $1.85 million average estimate based on two analysts.Gross profit- Subscription and support: $137.28 million compared to the $140.48 million average estimate based on two analysts.View all Key Company Metrics for BlackLine here>>>
Shares of BlackLine have returned -7.5% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
BlackLine (BL - Free Report) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +24.92%. A quarter ago, it was expected that this company would post earnings of $0.58 per share when it actually produced earnings of $0.63, delivering a surprise of +8.62%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
BlackLine, which belongs to the Zacks Internet - Software industry, posted revenues of $183.16 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.25%. This compares to year-ago revenues of $166.93 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
BlackLine shares have lost about 39.5% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for BlackLine?While BlackLine has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for BlackLine was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.57 on $187.33 million in revenues for the coming quarter and $2.39 on $765.24 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, NCR Atleos (NATL - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 6.
This provider of ATM services is expected to post quarterly earnings of $1.00 per share in its upcoming report, which represents a year-over-year change of +56.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
NCR Atleos' revenues are expected to be $1.04 billion, up 6.5% from the year-ago quarter.
CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat
CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
NYSE:KO
Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares
2 hours ago
Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,054 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $60.37, for a total transaction of $15,759,829.98. Following the completion of the sale, the insider owned 2,671,855 shares in the company, valued at $161,299,886.35. This represents a 8.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in Stock
2 hours ago
Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,055 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $63.02, for a total value of $16,451,686.10. Following the completion of the transaction, the insider owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of Stock
2 hours ago
Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 749,999 shares of Dutch Bros stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $60.39, for a total transaction of $45,292,439.61. Following the completion of the sale, the chairman owned 2,671,855 shares of the company's stock, valued at $161,353,323.45. This represents a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 750,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $63.02, for a total value of $47,265,000.00. Following the sale, the chairman owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
BlackLine (BL - Free Report) closed the last trading session at $30.63, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $45.62 indicates a 48.9% upside potential.
The average comprises 13 short-term price targets ranging from a low of $32.00 to a high of $70.00, with a standard deviation of $11.74. While the lowest estimate indicates an increase of 4.5% from the current price level, the most optimistic estimate points to a 128.5% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
However, an impressive consensus price target is not the only factor that indicates a potential upside in BL. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why BL Could Witness a Solid UpsideAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 2.8%, as two estimates have moved higher compared to no negative revision.
Moreover, BL currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much BL could gain, the direction of price movement it implies does appear to be a good guide.
BlackLine is downgraded to a hold rating due to a lack of expected growth acceleration despite solid product progress. Q1 showed revenue up ~10% y/y and strong metrics in deal size and RPO, but ARR growth remains weak at 8.5% y/y. BL's platform pricing and Verity AI adoption are progressing, but monetization and scaled deployment timing remain uncertain.
BlackLine is upgraded to a "Buy," driven by compelling value after a ~50% share price decline. BL's specialized accounting software is highly resistant to AI disruption, serving critical, error-intolerant finance processes. The company's sub-2% penetration of a $45 billion TAM and recent FedRAMP certification unlock significant growth opportunities.
LOS ANGELES, May 19, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) announced today that members of BlackLine’s management team will attend the following upcoming investor conferences:
Baird 2026 Global Consumer, Technology & Services Conference
Tuesday, June 2, 2026
Presentation time: 2:00 PM ET
Location: New York, NY
William Blair 46th Annual Growth Stock Conference
Wednesday, June 3, 2026
Presentation time: 10:00 AM CT
Location: Chicago, IL
Where available, webcasts will be accessible on BlackLine’s investor relations website at https://investors.blackline.com.
About BlackLine
BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations. Built on the Studio360 platform, BlackLine unifies data, streamlines processes, and delivers real-time insights through automation and intelligence powered by Verity - a comprehensive suite of embedded, auditable AI capabilities that provides finance and accounting teams with a new digital workforce.
With a proven, collaborative approach and a track record of innovation supported by industry-leading R&D investment and world-class security practices, more than 4,300 customers across multiple industries partner with BlackLine to lead their organizations into the future.
3 Dividend Stocks With Insiders Buying in 2026BlackLine NASDAQ: BL executives said finance and accounting departments are moving cautiously but steadily toward artificial intelligence, with demand centered on accuracy, controls and predictable economics rather than experimentation.
Speaking at the Baird Global Consumer, Technology & Services Conference, CEO Owen Ryan and CFO Patrick Villanova described an enterprise customer base that is interested in AI but reluctant to deploy tools that could introduce risk into financial reporting. Ryan said finance and accounting teams are trying to understand AI spending across their organizations, while many CFOs are questioning whether current AI investments are delivering real returns.
Get BlackLine alerts:
MarketBeat Week in Review – 05/04 - 05/08“In the accounting side, which is where we spend most of our efforts with our customers, we’re not seeing layoffs. We’re not seeing a lot of hiring,” Ryan said. He added that customers are asking BlackLine to help define “the art of the possible” for AI use cases and to co-develop capabilities that can be deployed responsibly.
Ryan said large companies are generally not looking to be on the “bleeding edge,” given the involvement of management teams, internal auditors, external auditors and regulators. He said BlackLine supports a significant portion of capital markets activity, stating that “$54 trillion of market cap runs through BlackLine every day.”
Accounting AI Adoption Remains Cautious Is Backblaze the Next Momentum Monster?Villanova said AI use cases are currently more prevalent in finance than accounting because forecasting does not require perfect accuracy. Accounting, by contrast, demands exact results.
“If you’re 95% right in the accounting world, you’re 100% wrong,” Villanova said. “If you’re 5% off your financial statements, that’s a restatement. That’s a lawsuit. People lose their jobs.”
Villanova said that risk profile makes it difficult for companies to justify building accounting AI capabilities on their own simply to save money. He said BlackLine’s history and reputation give it an advantage with customers seeking guardrails, controls and human oversight.
Ryan said the slower pace of adoption could be a tailwind for BlackLine because its enterprise customers need solutions that can satisfy CIOs, legal teams, auditors and regulators. He said the company was criticized last year for not moving faster with AI, but argued that BlackLine’s customer base requires a more deliberate approach.
Platform Pricing and Studio 360 Drive Customer Conversations Villanova said BlackLine’s platform pricing model, launched in January 2024, is gaining traction with new customers. He said more than 90% of new logos are choosing the platform model, which offers unlimited access and unlimited users.
For existing customers, adoption was initially slower, but Villanova said the launch of Studio 360 helped shift the discussion from user access to product value. He described Studio 360 as the “connective fiber” of BlackLine’s platform, providing one source of truth and one data set.
Villanova said BlackLine has reached 13% of eligible annual recurring revenue on platform pricing and reiterated that the company expects to reach at least 25% by the end of the year. He said achieving that target would mean more than 50% of customer ARR would be consumption-only, with no link to user counts.
Ryan said new customers have been highly receptive to platform pricing, but some of BlackLine’s most deeply adopted customers have been harder to convert because they want to see additional return on investment. He said AI has helped elevate conversations with customers to higher levels in the organization, including CFOs.
Executives Outline Monetization of AI Agents Villanova said customers moving to the platform are producing a day-one ARR uplift of 10% to 40%. While that pulls some future user additions forward, he said BlackLine’s modeling shows the uplift more than offsets the user additions it would otherwise expect.
He described three expected economic benefits from the platform transition:
A day-one ARR uplift when customers move to platform pricing; Reduced attrition tied to user-seat reductions; Additional revenue from increased consumption of AI agents over time. Villanova said customers receive a limited number of agents initially so finance teams can test them, gain comfort from internal and external auditors, and run agent outputs alongside manual processes. He said public companies typically need two to three quarters of testing before applying agents more broadly.
Ryan and Villanova also emphasized that BlackLine is not selling tokens. Ryan said tokenization has become a concern for CFOs because costs can spiral without clear ROI. Villanova said BlackLine sells outcomes, such as automating financial transactions, rather than charging customers based on token usage.
“You’re not going to be able to sell to a person like me saying, ‘We have no idea how many tokens you’re going to use, and we’re going to charge you for it,’” Villanova said.
SAP Partnership, Churn and Capital Allocation Ryan said BlackLine is in ongoing conversations with SAP about changing pricing for SAP Solution Extension, or SolEx, customers. He said some BlackLine AI capabilities on the agentic side are not currently available to SolEx customers and that those customers are likely to push for change.
Ryan also said BlackLine and SAP are working on AI initiatives involving SAP’s Joule capabilities and BlackLine’s Verity capabilities. He said the companies have a memorandum of understanding in progress and several working sessions planned over the next six to eight weeks.
Villanova addressed churn in BlackLine’s lower mid-market customer segment, saying the company sold during COVID to smaller customers with five to 10 accountants that were not scaling or adopting the product effectively. He said BlackLine decided in 2023 to stop selling to those customers and expects the related churn to improve in the second half of this year as three-year contracts from that cohort roll off.
On capital allocation, Villanova said BlackLine’s first priority is investing in its own product innovation. He said the company also continues to evaluate tuck-in acquisitions that could expand its platform and capabilities for the office of the CFO. Share repurchases remain a third use of capital, he said, with the company continuing to evaluate buybacks opportunistically.
Federal Opportunity Tied to Compliance Progress Ryan said BlackLine sees an opportunity in aerospace, defense and federal government markets as it progresses through compliance requirements, including IL-2 and IL-4. He said BlackLine has historically been able to sell into the commercial side of aerospace and defense customers, but not the government side.
Ryan said the company has had “a couple smaller wins” and is building a pipeline in the federal government space. He said the third quarter is where BlackLine expects to begin seeing some success, though he added that the government market moves more slowly than commercial markets.
“Our real bet for this is in 2027,” Ryan said, adding that BlackLine aims to help government departments and agencies become auditable.
About BlackLine NASDAQ: BLBlackLine, Inc is a leading provider of cloud-based software solutions designed to automate and modernize the finance and accounting function. The company's flagship offering, the BlackLine Finance Controls and Automation Platform, enables organizations to streamline critical processes such as account reconciliations, journal entry management, intercompany accounting, and transaction matching. By delivering a centralized, real-time view of financial data, BlackLine helps companies improve operational efficiency, enhance compliance and strengthen internal controls.
Key products and services within the BlackLine platform include Account Reconciliation, Task Management, Transaction Matching, Journal Entry, and Intercompany Hub.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in BlackLine Right Now?Before you consider BlackLine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BlackLine wasn't on the list.
While BlackLine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
3 Dividend Stocks With Insiders Buying in 2026BlackLine NASDAQ: BL executives said the company is leaning on platform pricing, artificial intelligence and deeper enterprise adoption as it works to reaccelerate revenue growth, according to remarks at a William Blair conference session.
Chair and CEO Owen Ryan described BlackLine as a “mission-critical system for the office of the CFO,” saying the company supports financial close, reconciliation, intercompany, invoice-to-cash and reporting workflows. Ryan said BlackLine recently marked its 25th anniversary and serves about 4,400 customers across major global markets.
Get BlackLine alerts:
MarketBeat Week in Review – 05/04 - 05/08Ryan said BlackLine’s public-company customers represent about $54 trillion of market capitalization, underscoring the company’s role in helping organizations produce financial statements and meet audit and regulatory requirements. He added that BlackLine typically serves at least half of larger public companies in major markets and has about 60% penetration of the Fortune 500.
Studio 360 Positioned as Growth Driver Chief Financial Officer Patrick Villanova said BlackLine’s Studio 360 platform has changed the company’s go-to-market and product strategy by connecting what had historically been four separate solutions: Financial Close, Intercompany, Invoice-to-Cash and Financial Reporting & Analytics.
Is Backblaze the Next Momentum Monster?Villanova said Studio 360 provides a single data layer across those offerings, creating what he called a “single source of truth” for finance organizations. He said that structure is important both for customers seeking fewer systems to manage and for BlackLine’s AI strategy.
“For an agent to work in our world, it has to work off one data source,” Villanova said. He contrasted that with companies operating across dozens of ERP and finance systems, where AI tools could return different answers depending on the data source.
Villanova said the platform is opening cross-sell opportunities within the existing customer base. He said customers using three or more BlackLine solutions are “almost guaranteed” to be seven-figure annual recurring revenue customers, while customers using only one solution are less likely to reach that level.
Platform Pricing Brings Subscription Uplift Villanova outlined three monetization levers tied to BlackLine’s platform pricing model. First, he said customers moving to Studio 360 are seeing a 10% to 40% uplift in baseline subscription revenue. He said 13% of eligible annual recurring revenue is already on platform pricing, providing evidence that customers are willing to pay more for access to the technology.
Second, Villanova said the platform model reduces a historical source of attrition: user reductions. Under the platform model, he said customers receive unlimited users and a fixed fee, rather than paying based on seats.
Third, Villanova said BlackLine expects consumption-based pricing tied to AI agents to become the largest opportunity. The agents are designed to perform accounting and finance functions on a transaction basis. As more transactions are performed by agents, he said, BlackLine revenue can rise while customers see efficiency gains.
Villanova said BlackLine offers customers a sample of agent transactions for free as part of the uplift, allowing companies to validate that the agents perform work in line with internal policies, procedures and audit requirements. In public company settings, he said that validation typically takes a couple of quarters.
SAP Partnership Remains Central Ryan said BlackLine continues to have a longstanding relationship with SAP through SAP’s Solution Extension, or SolEx, partnership. He said about 26% of BlackLine’s revenue comes through working with SAP in the market through that relationship, though BlackLine also has SAP customers outside SolEx.
Ryan said the companies collaborate on product roadmaps, joint go-to-market efforts and customer success. He said SAP’s cloud transition has helped BlackLine, particularly when customers approach ERP migrations with finance transformation as an early priority.
Ryan cited ExxonMobil and Delta as examples of companies where BlackLine was part of broader SAP-related finance transformation efforts. He said the timing of large ERP migrations can be slow, but SAP’s eventual end of support for on-premises systems could become a catalyst.
Enterprise Focus Affects Customer Mix Ryan said BlackLine has become more selective about customers after previously selling software to companies that were not a strong fit. He said the company made a strategic decision in 2023 to wind down parts of the lower middle-market portfolio, and many of those customers had three-year contracts.
Ryan said BlackLine expects lower middle-market attrition to be “substantially done” by the end of the year. He said the shift has weighed on customer count, but new customers are substantially larger than those leaving.
He added that more than 90% of new customers in the first quarter went live with the platform “right out of the box,” reflecting the company’s focus on organizations committed to finance transformation.
Executives Point to Pipeline, RPO and AI Adoption Ryan said he is encouraged by seven or eight consecutive quarters of pipeline growth and by increased customer engagement in enterprise sales discussions. He also pointed to remaining performance obligations, or RPO, as evidence that customers are committing to longer-term transformation projects.
Villanova said pipeline generation increased in the second half of 2024, leading to bookings growth of more than 20% in 2025. He said continued pipeline growth supports confidence in more than 20% bookings growth in 2026, which he said would translate into low-teens revenue growth in 2027.
Villanova also said BlackLine’s RPO grew 23% in the fourth quarter and 18% in the first quarter, surpassing $1 billion for the first time. He described that as guaranteed current and future revenue, and said those financial data points underpin management’s confidence in the growth model.
On AI risks, Ryan said customers sometimes ask why they cannot build their own agents using large language models. He said BlackLine emphasizes the difference between producing a reconciliation once and performing it repeatedly at scale with the controls needed for auditors and regulators.
Ryan said BlackLine is also exploring ways for system integrators and business process outsourcing partners to build on its platform, subject to standards similar to an app store review process.
About BlackLine NASDAQ: BLBlackLine, Inc is a leading provider of cloud-based software solutions designed to automate and modernize the finance and accounting function. The company's flagship offering, the BlackLine Finance Controls and Automation Platform, enables organizations to streamline critical processes such as account reconciliations, journal entry management, intercompany accounting, and transaction matching. By delivering a centralized, real-time view of financial data, BlackLine helps companies improve operational efficiency, enhance compliance and strengthen internal controls.
Key products and services within the BlackLine platform include Account Reconciliation, Task Management, Transaction Matching, Journal Entry, and Intercompany Hub.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in BlackLine Right Now?Before you consider BlackLine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BlackLine wasn't on the list.
While BlackLine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
NEW YORK, April 14, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) will report first quarter 2026 financial results on Monday, May 4, 2026.
On that date the Company will also post earnings remarks on its website. These remarks will include commentary from the Company's Chief Executive Officer, Ben Tisch, and Chief Financial Officer, Jane Wang.
The news release and earnings remarks will be available online at the Loews Corporation website (www.loews.com).
About Loews Corporation
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality and packaging industries. For more information, please visit www.loews.com.
TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Loblaw has issued its March Food Inflation Report, with context around what’s impacting food prices and what it expects in the future.
Based on the latest StatsCan data, inflation climbed to 2.4% year over year in March, following a 1.8% increase the month prior. StatsCan attributes roughly 20 basis points of the March result to the ongoing crisis in the Middle East. The price of food purchased from stores rose in March as well, to 4.4%, with the price of fresh vegetables (+7.8%) seeing its largest increase in over two and a half years. Tighter supply and weather contributed to this result.
April 28, 2026 15:40 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- Out of an abundance of caution, Loblaw Companies Limited is recalling select cases of PC® Cola (12 x 355 ML) products with UPC 060383787035.
Inside some of the cases, cans labelled as PC® Cola Zero Sugar may contain regular PC® Cola. This may be a health concern for customers who are avoiding sugar.
Only products with the 2026NO20 PQ XXXX lot code are affected by the recall. The affected products were sold between April 2, 2026 and April 27, 2026 at the following stores:
Ontario: Real Canadian Superstore, Fortinos, Loblaws, Valu-Mart, Your Independent Grocer, Zehrs, No Frills, affiliated independent stores, Wholesale Club, no name store, Shoppers Drug Mart
Atlantic: Atlantic Superstore, Dominion, Your Independent Grocer, Maxi, No Frills, affiliated independent stores, Shoppers Drug Mart
Québec: Provigo, Maxi, Axep, Intermarché, Valu-Mart, Club Entrepôt, Pharmaprix
West: Real Canadian Superstore, Independent franchise stores, Your Independent Grocer, Extra Foods, No Frills, independent retail stores, Real Canadian Wholesale Club, Wholesale Club, Shoppers Drug Mart
All affected products have been removed from store shelves. Customers are encouraged to return the product to the place of purchase for a full refund.
We apologize for any inconvenience this may cause. The safety and trust of our customers remain our top priority.
For more information, customers can contact Customer Service at 1-888-495-5111 or visit: http://www.presidentschoice.ca/en_CA/customer-service-feedback-form.html
TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- It’s time to put your best foot forward for a cause that matters. Registration for the 2026 Shoppers Drug Mart® Run for Women is now open, and Canadians are invited to join a powerful movement.
As Canada’s largest run/walk series dedicated to women’s mental health, the Shoppers Drug Mart® Run for Women has raised over $27 million since 2013. Every dollar raised by participants and supporters directly fuels programs in their own communities, providing everything from crisis counselling and peer support groups to vital research and initiatives that reduce stigma.
Here’s how you can get involved
Whether you are walking or running, everyone can join the fun! Choose between a 5km or 10km route and participate solo or build a team with friends, family, or coworkers. Participants are encouraged to fundraise and those raising $150 or more can earn exciting rewards like PC Optimum™ points or Running Room gift cards.
Learn about the impact you’re having
The money raised across the 18 events funds local mental health charities and programs that expand access to care and support for women across Canada.
“The Shoppers Drug Mart® Run for Women is more than a national event, it’s a movement” shares Carrie Trembinski, Vice President, Communications and Community Engagement at St. Joseph’s Healthcare Foundation. “Together, we’re forging a path towards greater understanding, equity, and access to care for women experiencing mental health concerns. The Run celebrates the strength of women while building a community that makes women feel safe in asking for help when they need it. And that is powerful.”
Find your community, be part of the movement
Registration is now open for events taking place in 18 cities across Canada:
Moncton, NB (May 3, 2026)Vancouver, BC (May 9, 2026)Waterloo, ON (May 9, 2026)Edmonton, AB (May 23, 2026)Oakville, ON (May 23, 2026)Markham, ON (May 24, 2026)Montreal, QC (May 30, 2026)Victoria, BC (May 30, 2026)Ottawa, ON (May 31, 2026)Toronto, ON (June 6, 2026)Winnipeg, MB (June 6, 2026)Hamilton, ON (June 7, 2026)London, ON (June 13, 2026)Quebec City, QC (June 13, 2026)Saskatoon, SK (June 13, 2026)St. John’s, NL (June 13, 2026)Calgary, AB (June 20, 2026)Whitby, ON (June 20, 2026)
Whether you join an event or choose to donate, your support helps create a future where every woman in Canada can access the mental health care she deserves.
To sign up for an event in your community or to donate today, visit runforwomen.ca.
About Shoppers Foundation for Women’s HealthTM
Shoppers Foundation for Women’s HealthTM – the charitable arm of Shoppers Drug Mart® – is committed to helping Canadian women lead healthier lives, by making care more equitable and accessible. In 2022, the Foundation set an ambitious goal: to contribute $50M by 2026 towards women’s health initiatives that are making care more equitable and accessible. This milestone has been surpassed, ahead of schedule, and Shoppers Foundation remains steadfast in its commitment to build a future in which more women in Canada can lead healthier lives." Learn more at shoppersfoundation.ca.
About Shoppers Drug Mart Inc.
Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns more than 150 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec). In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities and Lifemark Health Group, Canada’s leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited.
BRAMPTON, Ontario, April 30, 2026 (GLOBE NEWSWIRE) -- Prepare to satisfy every craving and comfort every emotion! Loblaws®, Zehrs®, and Your Independent Grocer® are thrilled to unveil their new multi-channel “FOODS FOR ALL THE MOODS" brand platform this spring. This platform and campaign are a rich and vibrant celebration of life's moments, big and small, demonstrating how our trusted stores and colleagues consistently provide the perfect food solutions for every mood and occasion. Joining this exciting journey is the beloved culinary expert and television personality, Antoni Porowski, making a fun and engaging return.
“We know that food plays a spectrum of different roles in people’s lives. It has the incredible power to impact, address and change emotions,” says Shelley Tangney, VP of Marketing for the Super Market division at Loblaw Companies Ltd. “Every day, our customers pair what they eat with what they are feeling. Our new “FOODS FOR ALL THE MOODS” content reflects that daily ritual in relatable and playful ways that invites everyone to engage.”
The campaign begins with Antoni assisting customers in relatable scenarios. The spot features him rescuing an overwhelmed dad who is juggling both a stroller and a work call, by arriving with PC Express bags and jokingly proclaiming, "We also deliver!", highlighting the ease and accessibility of grocery delivery services.
The campaign with Antoni will continue into summer, supporting fans through the extreme highs and lows of a soccer match. He appears with two fresh baked cakes, one that says "GOALLL," and one that says "NOOOO", showcasing that stores are ready to cover all game-time emotions from celebration to commiseration.
“People naturally reach for foods that match how they feel, and Antoni is the perfect ‘food-mood matchmaker,’ helping show Canadians how easy it is to find the right food for every mood or moment,” says Bryan Collins, Founder & CCO, ONE23WEST.
The "FOODS FOR ALL THE MOODS" campaign will roll out across television, digital, social media, and in-store channels starting this spring.
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca
Photos accompanying this announcement are available at:
, /PRNewswire/ -- Loews Corporation (NYSE: L) today released its first quarter 2026 financial results.
First Quarter 2026 highlights:
Loews Corporation reported net income of $337 million, or $1.63 per share, in the first quarter of 2026, compared to $370 million, or $1.74 per share, in the first quarter of 2025. The following are key highlights of our first quarter results:
CNA Financial Corporation's (NYSE: CNA) net income attributable to Loews Corporation decreased year-over-year primarily due to lower underlying underwriting results and unfavorable net prior year loss reserve development, partially offset by higher net investment income. Boardwalk Pipelines' net income increased year-over-year primarily due to higher contracting rates and utilization-based revenues on gas transportation, as well as higher rates on storage, parking and lending. Loews Hotels' net income increased year-over-year primarily due to higher equity income from joint ventures, driven mainly by the Universal Orlando Resort joint ventures. Corporate segment results decreased year-over-year primarily due to lower investment income from the parent company trading portfolio and higher interest expense. Book value per share increased to $90.90 as of March 31, 2026, from $90.71 as of December 31, 2025. Book value per share, excluding AOCI, increased to $97.20 as of March 31, 2026, from $95.89 as of December 31, 2025. On March 31, 2026, the parent company had $4.5 billion of cash and investments and $1.8 billion of debt. Loews Corporation repurchased 0.3 million shares of its common stock during the first quarter of 2026 for a total cost of $31 million. Consolidated highlights:
Three Months Ended March 31,
(In millions)
2026
2025
Net Income (Loss) Attributable to Loews Corporation:
CNA Financial
$ 194
$ 252
Boardwalk Pipelines
159
152
Loews Hotels & Co
26
—
Corporate
(42)
(34)
Net income attributable to Loews Corporation
$ 337
$ 370
Net income per share attributable to Loews Corporation
$ 1.63
$ 1.74
March 31, 2026
December 31, 2025
Book value per share
$ 90.90
$ 90.71
Book value per share excluding AOCI
$ 97.20
$ 95.89
Shares of common stock outstanding (in millions)
205.8
206.0
Three months ended March 31, 2026 compared to 2025
CNA:
Net income attributable to Loews Corporation was $194 million compared to $252 million. Core income decreased to $225 million compared to $281 million, driven by lower underlying underwriting results and unfavorable net prior year loss reserve development, partially offset by higher net investment income. Net earned premiums grew by 3% and net written premiums grew by 1%. Property and Casualty's combined ratio increased by 3.8 points to 102.2% compared to 98.4% largely due to a higher underlying loss ratio and unfavorable net prior year loss reserve development. Property and Casualty's underlying combined ratio increased to 94.5% from 92.1%. Property and Casualty's underlying loss ratio increased by 2.6 points, mainly driven by higher loss cost trends and lower than expected rate in certain lines in recent quarters. Property and Casualty's unfavorable net prior year loss reserve development increased from $61 million to $100 million mainly driven by professional errors & omissions and excess casualty in recent accident years. Net investment income increased due to higher income from fixed income securities, as a result of a larger invested asset base and favorable reinvestment rates, partially offset by lower common stock returns. Boardwalk:
Net income increased to $159 million compared to $152 million. EBITDA increased to $360 million compared to $346 million. Net income and EBITDA improved due to higher contracting rates and utilization-based revenues on gas transportation as well as higher rates on storage, parking and lending, partially offset by lower product sales and higher operating expenses. Loews Hotels:
Net income increased to $26 million compared to less than $1 million. Adjusted EBITDA increased 53% to $124 million compared to $81 million. Net income and adjusted EBITDA improved primarily due to higher equity income from joint ventures driven by growth in the overall average daily rate and an increase in both the number of available and the number of occupied room nights at the Universal Orlando Resort, including the addition of the three new hotels that opened in 2025. Corporate:
Net loss of $42 million compared to a net loss of $34 million. Results decreased primarily due to lower investment income from the parent company trading portfolio and higher interest expense related to recent debt refinancing. Share Purchases:
On March 31, 2026, there were 205.8 million shares of Loews common stock outstanding. During the three months ended March 31, 2026, Loews Corporation repurchased 0.3 million shares of its common stock for a total cost of $31 million. Depending on market conditions, Loews may from time to time purchase shares of its and its subsidiaries' outstanding common stock in the open market (including, with respect to Loews common stock, in open market transactions that may or may not satisfy all of the conditions of the Rule 10b-18 voluntary safe harbor), in privately negotiated transactions or otherwise. Reconciliation of GAAP Measures to Non-GAAP Measures
This news release contains financial measures that are not in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Management believes some investors may find these measures useful to evaluate our and our subsidiaries' financial performance. CNA utilizes core income, underlying loss ratio and underlying combined ratio. Boardwalk utilizes earnings before interest, income tax expense, depreciation and amortization ("EBITDA"), and Loews Hotels utilizes Adjusted EBITDA. These non-GAAP measures are defined and reconciled to the most comparable GAAP measures on pages 6 and 7 of this release.
Earnings Remarks
For Loews Corporation
Today, May 4, 2026, earnings remarks will be available on the Investors section of our website at www.loews.com. Remarks will include commentary from Loews's president and chief executive officer and chief financial officer. For CNA
Today, May 4, 2026, earnings remarks will be available on the Investor Relations section of CNA's website at www.cna.com. Remarks will include commentary from CNA's president and chief executive officer and chief financial officer. About Loews Corporation
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality and packaging industries. For more information, please visit www.loews.com.
Forward-Looking Statements
Statements contained in this news release which are not historical facts are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are inherently uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by the Company. A discussion of the important risk factors and other considerations that could materially impact these matters, as well as the Company's overall business and financial performance, can be found in the Company's reports filed with the Securities and Exchange Commission and readers of this release are urged to review those reports carefully when considering these forward-looking statements. Copies of these reports are available through the Company's website (www.loews.com). Given these risk factors, investors and analysts should not place undue reliance on forward-looking statements. Any such forward-looking statements speak only as of the date of this news release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any forward-looking statement is based.
Loews Corporation and Subsidiaries
Selected Financial Information
Three Months Ended March 31,
(In millions)
2026
2025
Revenues:
CNA Financial (a)
$ 3,677
$ 3,627
Boardwalk Pipelines
631
622
Loews Hotels & Co
254
245
Corporate investment income (loss), net and other
(7)
—
Total
$ 4,555
$ 4,494
Income (Loss) Before Income Tax:
CNA Financial (a)
$ 267
$ 349
Boardwalk Pipelines
211
202
Loews Hotels & Co
37
4
Corporate:
Investment income (loss), net
(4)
—
Other (b)
(48)
(41)
Total
$ 463
$ 514
Net Income (Loss) Attributable to Loews Corporation:
CNA Financial (a)
$ 194
$ 252
Boardwalk Pipelines
159
152
Loews Hotels & Co
26
—
Corporate:
Investment income (loss), net
(3)
—
Other (b)
(39)
(34)
Net income attributable to Loews Corporation
$ 337
$ 370
(a)
The three months ended March 31, 2026 and 2025 include net investment losses of $18 million and $9 million ($13 million and $6 million after tax and noncontrolling interests).
(b)
Consists of parent company interest expense, corporate expenses and the equity income (loss) of Altium Packaging.
Loews Corporation and Subsidiaries
Consolidated Financial Review
Three Months Ended March 31,
(In millions, except per share data)
2026
2025
Revenues:
Insurance premiums
$ 2,699
$ 2,626
Net investment income
613
608
Investment losses
(18)
(9)
Operating revenues and other
1,261
1,269
Total
4,555
4,494
Expenses:
Insurance claims and policyholders' benefits
2,175
2,027
Operating expenses and other
1,917
1,953
Total
4,092
3,980
Income before income tax
463
514
Income tax expense
(109)
(122)
Net income
354
392
Amounts attributable to noncontrolling interests
(17)
(22)
Net income attributable to Loews Corporation
$ 337
$ 370
Net income per share attributable to Loews Corporation
$ 1.63
$ 1.74
Weighted average number of shares
206.27
212.60
Definitions of Non-GAAP Measures and Reconciliation of GAAP Measures to Non-GAAP Measures:
CNA Financial Corporation
Core income is calculated by excluding from CNA's net income attributable to Loews Corporation the after-tax effects of investment gains or losses and gains or losses resulting from pension settlement transactions. In addition, core income excludes the effects of noncontrolling interests. The calculation of core income excludes investment gains or losses because they are generally driven by economic factors that are not necessarily reflective of CNA's primary insurance operations. The calculation of core income excludes gains or losses resulting from pension settlement transactions as they result from decisions regarding CNA's defined benefit pension plans which are unrelated to its primary insurance operations.
The following table presents a reconciliation of CNA net income attributable to Loews Corporation to core income:
Three Months Ended March 31,
(In millions)
2026
2025
CNA net income attributable to Loews Corporation
$ 194
$ 252
Investment losses
14
7
Noncontrolling interests
17
22
Core income
$ 225
$ 281
In evaluating the results of Property & Casualty operations, CNA utilizes the loss ratio, the underlying loss ratio, the expense ratio, the dividend ratio, the combined ratio and the underlying combined ratio. These ratios are calculated using GAAP financial results. The loss ratio is the percentage of net incurred claim and claim adjustment expenses to net earned premiums. The underlying loss ratio excludes the impact of catastrophe-related reinstatement premiums, catastrophe losses and development-related items from the loss ratio. Development-related items represent net prior year loss reserve and premium development, and includes the effects of interest accretion and change in allowance for uncollectible reinsurance. The expense ratio is the percentage of insurance underwriting and acquisition expenses, including the amortization of deferred acquisition costs, to net earned premiums. The dividend ratio is the ratio of policyholders' dividends incurred to net earned premiums. The combined ratio is the sum of the loss ratio, the expense ratio and the dividend ratio. The underlying combined ratio is the sum of the underlying loss ratio, the expense ratio and the dividend ratio. The underlying loss ratio and the underlying combined ratio are deemed to be non-GAAP financial measures, and management believes some investors may find these ratios useful to evaluate CNA's underwriting performance since they remove the impact of catastrophe losses which are unpredictable as to timing and amount, and development-related items as they are not indicative of current year underwriting performance.
The following table presents a reconciliation of CNA's loss ratio to underlying loss ratio and CNA's combined ratio to underlying combined ratio:
Three Months Ended March 31,
2026
2025
Loss ratio
71.8 %
67.8 %
Expense ratio
29.9
30.2
Dividend ratio
0.5
0.4
Combined ratio
102.2 %
98.4 %
Less: Effect of catastrophe impacts
3.6
3.8
Less: Effect of development-related items
4.1
2.5
Underlying combined ratio
94.5 %
92.1 %
Underlying loss ratio
64.1 %
61.5 %
Boardwalk Pipelines
EBITDA is defined as earnings before interest, income tax expense, depreciation and amortization. The following table presents a reconciliation of Boardwalk's net income attributable to Loews Corporation to its EBITDA:
Three Months Ended March 31,
(In millions)
2026
2025
Boardwalk net income attributable to Loews Corporation
$ 159
$ 152
Interest, net
38
38
Income tax expense
52
50
Depreciation and amortization
111
106
EBITDA
$ 360
$ 346
Loews Hotels & Co
Adjusted EBITDA is calculated by excluding from Loews Hotels & Co's EBITDA, the noncontrolling interest share of EBITDA adjustments, gains or losses on asset acquisitions and dispositions, asset impairments, and equity method income, and including Loews Hotels & Co's pro rata Adjusted EBITDA of equity method investments. Pro rata Adjusted EBITDA of equity method investments is calculated by applying Loews Hotels & Co's ownership percentage to the underlying equity method investment's components of Adjusted EBITDA and excluding distributions in excess of basis.
The following table presents a reconciliation of Loews Hotels & Co net income attributable to Loews Corporation to its Adjusted EBITDA:
Three Months Ended March 31,
(In millions)
2026
2025
Loews Hotels & Co net income attributable to Loews Corporation
$ 26
$ —
Interest, net
12
13
Income tax expense
11
4
Depreciation and amortization
26
24
EBITDA
75
41
Noncontrolling interest share of EBITDA adjustments
(1)
Asset impairments
9
Equity investment adjustments:
Loews Hotels & Co's equity method income
(44)
(6)
Pro rata Adjusted EBITDA of equity method investments
83
46
Consolidation adjustments
1
1
Adjusted EBITDA
$ 124
$ 81
The following table presents a reconciliation of Loews Hotels & Co's equity method income to the Pro rata Adjusted EBITDA of its equity method investments:
Three Months Ended March 31,
(In millions)
2026
2025
Loews Hotels & Co's equity method income
$ 44
$ 6
Pro rata share of equity method investments:
Interest, net
17
10
Income tax expense
Depreciation and amortization
17
13
Asset impairments
9
Distributions in excess of basis
7
9
Other adjustments
(2)
(1)
Pro rata Adjusted EBITDA of equity method investments
May 04, 2026 07:00 ET | Source: Loblaw Companies Limited
TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L; “Loblaw” or the “Company”) has partnered with Canadian technology firm Shakudo, as the Company continues to accelerate AI adoption to enhance its customer shopping experience and enhance its organizational capabilities. Shakudo’s platform enables companies to manage and scale AI, machine learning, and data infrastructure within complex technological environments. Loblaw will use this platform to build and run first-party AI applications, creating a centralized and consistent environment for its Digital and Technology & Analytics teams.
This partnership reflects Loblaw’s commitment to supporting Canadian innovation and technology, and marks another key milestone in the company’s ongoing efforts to increase its capabilities of rapidly deploying advanced systems and building ready-to-use tools internally.
“Speed matters, but standards matter more,” said Charu Pujari, Senior Vice President, Engineering and AI at Loblaw. “By partnering with Shakudo, we’ve given our teams a common platform to build on – so they can focus on solving real problems instead of reinventing core plumbing. It’s how we scale agentic capabilities responsibly, across many teams, without fragmentation.”
This partnership is central to how Loblaw builds AI: enabling faster development and consistent execution, while maintaining strict governance and oversight across all autonomous, agent-driven operations. As part of its AI integration strategy, Loblaw is establishing internal protocols that allow AI applications to securely interact with enterprise systems. Teams will use secure servers to coordinate AI-driven workflows, enhancing efficiency while maintaining governance and oversight.
“Loblaw is building exactly the kind of AI-native platform we designed Shakudo for,” said Yevgeniy Vahlis, Founder of Shakudo. “They’re not experimenting at the edges, they’re operationalizing agent orchestration at enterprise scale, with real standards, real workflows, and real impact. It’s exciting to see a Canadian company use Canadian AI technology as the backbone of such an ambitious effort.”
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
About Shakudo
Shakudo's operating system for AI helps enterprises accelerate their time to market with AI without ever sending their data out to third parties. By deploying within customers' own infrastructure, Shakudo delivers the flexibility of open-source tooling with enterprise-grade security—keeping sensitive data sovereign while unlocking AI capabilities across the organization.
Loews Corp (NYSE:L) reported lower first quarter 2026 earnings, with net income declining year-over-year amid weaker insurance underwriting results and higher corporate costs, even as its pipeline and hotel businesses posted gains.
Shares of the conglomerate, which has business interests in insurance, energy, hospitality and packaging, fell nearly 4% following the results.
For the quarter ended March 31, 2026, the company reported net income of $337 million, or $1.63 per diluted share, compared with $370 million, or $1.74 per share, in the same period a year earlier.
Revenue rose slightly to $4.56 billion from $4.49 billion.
The company said the decline in earnings was primarily driven by CNA Financial Corporation, where results were pressured by lower underlying underwriting performance and unfavorable prior-year reserve development, partially offset by higher net investment income.
Boardwalk Pipelines reported higher net income year-over-year, supported by stronger contracting rates and increased utilization-based revenue in gas transportation, along with improved pricing in storage, parking and lending services.
Loews Hotels also posted an increase in net income, reflecting higher equity income from joint ventures, particularly tied to the Universal Orlando Resort partnerships.
These gains were partly offset by weaker corporate segment results, which reflected lower investment income from the parent company’s trading portfolio as well as higher interest expenses.
Book value per share rose slightly to $90.90 as of March 31, 2026, compared with $90.71 at the end of 2025. Book value per share excluding accumulated other comprehensive income increased to $97.20 from $95.89 over the same period.
Loews reported $4.5 billion in cash and investments at the parent company level, alongside $1.8 billion in debt as of quarter-end.
The company also repurchased 0.3 million shares during the quarter for $31 million.
BRAMPTON, Ontario, May 06, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L) (“Loblaw” or the “Company”) announced today its unaudited financial results for the first quarter ended March 28, 2026(1).
Loblaw delivered a strong first quarter with positive sales momentum. Continued same-store sales growth in Food Retail, increased customer traffic, e-commerce sales growth, and new store openings drove topline performance. The Company's discount banners outperformed again, demonstrating that Canadians are responding well to greater access to Maxi and NoFrills® stores. E-commerce sales were led by growth in PC Express™ delivery, plus the successful integration of third-party delivery options. In Drug Retail, growth continued to reflect positive trends in prescription volumes, specialty drugs, and beauty categories. Drug Retail performance underscored the strength of the Company’s healthcare services and commitment to meeting the evolving needs of Canadians. Loblaw continued its focus on strategic expansion and innovation during the quarter, including opening 5 Hard Discount stores and 8 drug stores, bringing convenient access to nutritious food and essential healthcare services to more communities.
“We are very pleased that our strategic investments in opening new stores, and our focus on value, are resonating with Canadians and helping us to deliver strong financial results,” said Per Bank, President and Chief Executive Officer, Loblaw Companies Limited. “From the breadth of our banners and the continued growth of PC Express™ delivery, to the consistent strength of our pharmacy services, we are demonstrating our commitment to being there when and where our customers need us most.”
2026 FIRST QUARTER HIGHLIGHTS
Retail revenue was $14,484 million, an increase of $580 million, or 4.2%. Retail revenue increased by 4.5%, excluding the impact of revenue related to Wellwise by Shoppers (“Wellwise”) and the Theodore & Pringle® optical business. Food Retail (Loblaw) same-store sales increased by 2.4%.Drug Retail (Shoppers Drug Mart) same-store sales increased by 4.1%, with pharmacy and healthcare services same-store sales growth of 6.7% and front store same-store sales growth of 1.0%.E-commerce sales increased by 20.3%. Revenue (including Retail and PC Financial)(2) was $14,724 million, an increase of $589 million, or 4.2%.Retail gross profit percentage(2) of 31.4% was stable, decreasing by 10 basis points, primarily driven by changes in sales mix in Drug Retail categories, partially offset by continued improvements in shrink. Food Retail gross margin was flat.Retail operating income was $1,010 million, an increase of $172 million, or 20.5%.Retail adjusted EBITDA(2) was $1,607 million, an increase of $98 million, or 6.5%. Selling, general and administrative expenses (“SG&A”) as a percentage of sales was 20.3%, a decrease of 40 basis points. Net earnings available to common shareholders of the Company were $594 million, an increase of $91 million or 18.1%. Diluted net earnings per common share were $0.50, an increase of $0.08, or 19.0%. The increase included the impact of lower amortization related to certain intangible assets associated with the 2014 acquisition of Shoppers Drug Mart, which are now fully amortized.Adjusted net earnings available to common shareholders of the Company(2) were $609 million, an increase of $39 million, or 6.8%. Adjusted diluted net earnings per common share(2) were $0.52, an increase of $0.05, or 10.6%.Repurchased for cancellation 10.2 million common shares at a cost of $648 million. Gross capital investments were $312 million.Free cash flow(2) from Retail was $432 million, an increase of $729 million.In connection with the sale of PC Financial, Loblaw expects to receive approximately $600 million in cash, representing the release of excess capital, cash consideration from EQB Inc., and collection of certain commodity tax receivables.Quarterly common share dividend increased by 10%, marking the fifteenth consecutive year of dividend increases. CONSOLIDATED RESULTS OF OPERATIONS
The following table provides key performance metrics for the Company. Unless otherwise indicated, all financial information represents the Company’s results from continuing operations (Retail). PC Financial results are presented as discontinued operations.
For the periods ended March 28, 2026 and March 22, 2025 2026
2025
(millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks)Revenue $14,484 $13,904 Gross profit(2) $4,548 $4,384 Gross profit %(2) 31.4% 31.5%Operating income $1,010 $838 Adjusted operating income(2) 998 934 Adjusted EBITDA(2) $1,607 $1,509 Adjusted EBITDA margin(2) 11.1% 10.9%Net interest expense and other financing charges $181 $162 Adjusted net interest expense and other financing charges(2) 181 162 Earnings before income taxes $829 $676 Income taxes $217 $176 Adjusted income taxes(2) 214 205 Net earnings attributable to non-controlling interests $25 $19 Total Company Adjusted EBITDA(2) $1,687 $1,591 Continuing operations 1,607 1,509 Discontinued operations 80 82 Net earnings available to common shareholders of the Company $594 $503 Continuing operations 587 481 Discontinued operations 7 22 Adjusted net earnings available to common shareholders of the Company(2) $609 $570 Continuing operations 578 548 Discontinued operations 31 22 Diluted net earnings per common share(4)($) $0.50 $0.42 Continuing operations 0.50 0.40 Discontinued operations — 0.02 Adjusted diluted net earnings per common share(2),(4)($) $0.52 $0.47 Continuing operations 0.49 0.45 Discontinued operations 0.03 0.02 Diluted weighted average common shares outstanding(4)(in millions) 1,178.2 1,210.3 Revenue represents retail revenue, and is primarily comprised of Food Retail and Drug Retail sales. The following table provides a breakdown of the Company’s total and same-store sales.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025 (millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks) SalesSame-store
sales SalesSame-store
sales Sales
$ ChangeSales
% ChangeFood Retail(i) $ 10,238 2.4 % $9,8542.2% $3843.9%Drug Retail 4,246 4.1 % 4,0503.8% 1964.8 %Pharmacy and healthcare services 2,384 6.7 % 2,2016.4% 1838.3 %Front store 1,862 1.0 % 1,8490.9% 130.7 %Revenue $ 14,484 $13,904 $5804.2 %PC Financial revenue (discontinued operations) 240 231 93.9 %Revenue (including Retail and PC Financial) $ 14,724 $14,135 $5894.2 % (i)As a result of the announcement of the sale of PC Financial, Food Retail sales now includes revenue related to PC Services, primarily related to sales attributable to The Mobile Shop™ in the current and comparative period presented, including revenue of $69 million in the first quarter of 2026 (2025 – $67 million). RETAIL RESULTS (CONTINUING OPERATIONS)
In the first quarter of 2026, Retail revenue was $14,484 million, an increase of $580 million, or 4.2%. Retail revenue increased by 4.5%, excluding the impact of revenue related to Wellwise and the Theodore & Pringle® optical business. Food Retail (Loblaw) sales were $10,238 million, an increase of $384 million, and same-store sales grew by 2.4% (2025 – 2.2%). The Company’s internal food inflation was significantly lower than the Consumer Price Index for Food Purchased From Stores of 4.4% (2025 – 2.6%); andFood Retail traffic increased and basket size increased on a same-store sales basis. Drug Retail (Shoppers Drug Mart) sales were $4,246 million, an increase of $196 million, and same-store sales grew by 4.1% (2025 – 3.8%). Pharmacy and healthcare services same-store sales growth was 6.7% (2025 – 6.4%), led by specialty prescriptions. On a same-store basis, the number of prescriptions increased by 2.8% (2025 – 2.3%) and the average prescription value increased by 5.0% (2025 – 4.4%).Front store same-store sales growth was 1.0% (2025 – 0.9%), primarily driven by higher sales of beauty products, with performance moderated by a shift in timing of the cough, cold, and flu season, and inclement weather. The sale of Wellwise and the wind-down of the Theodore & Pringle® optical business were completed in 2025. Revenue related to Wellwise and the optical business in the first quarter of 2026 was nil (2025 – $21 million and $18 million, respectively).In the first quarter of 2026, 13 food and drug stores were opened and 2 food and drug stores were closed. Retail square footage was 73.5 million square feet, a net increase of 1.2 million square feet, or 1.7%, compared to the first quarter of 2025. Gross profit(2) in the first quarter of 2026 was $4,548 million, an increase of $164 million, or 3.7%. Gross profit percentage(2) of 31.4% was stable, decreasing by 10 basis points, primarily driven by changes in sales mix in Drug Retail categories, partially offset by continued improvements in shrink. Food Retail gross margin was flat.Operating income in the first quarter of 2026 was $1,010 million, an increase of $172 million, or 20.5%.Adjusted EBITDA(2) in the first quarter of 2026 was $1,607 million, an increase of $98 million, or 6.5%. The increase was driven by an increase in gross profit(2), partially offset by an increase in SG&A. SG&A as a percentage of sales was 20.3%, a favourable decrease of 40 basis points, primarily due to operating leverage from higher sales and the timing of certain costs, partially offset by incremental costs related to opening new stores and the automated distribution facility.Depreciation and amortization in the first quarter of 2026 was $619 million, a decrease of $72 million, or 10.4%, primarily driven by the impact of lower amortization related to certain intangible assets associated with the 2014 acquisition of Shoppers Drug Mart Corporation (“Shoppers Drug Mart”), which are now fully amortized, partially offset by an increase in depreciation of leased assets and fixed assets related to opening new stores and the automated distribution facility. Included in depreciation and amortization was the amortization of intangible assets related to the acquisitions of Shoppers Drug Mart and Lifemark Health Group (“Lifemark”) of $10 million (2025 – $116 million). PC FINANCIAL RESULTS (DISCONTINUED OPERATIONS)
As previously announced in 2025, the Company entered into an agreement with EQB Inc. (“EQB”) pursuant to which EQB will acquire President’s Choice Bank (“PC Bank”) and certain other affiliated entities (collectively, “PC Financial”) (the “Sale of PC Financial”). EQB will acquire PC Financial for consideration satisfied through a combination of 7.2 million EQB shares and cash, subject to adjustment pursuant to the terms of the agreement.
Subsequent to the end of the first quarter of 2026, the Company and EQB announced that they obtained all required regulatory approvals for the Sale of PC Financial. The transaction is anticipated to close in the Company's third quarter of 2026, subject to customary closing conditions.
Upon closing, the Company will begin to recognize its proportionate share of EQB’s net income within its consolidated financial results. The Company and EQB have different fiscal year and quarter ends. As a result of this difference, the Company will recognize its proportionate share of EQB’s net income based on the most recent publicly available information at each of the Company’s fiscal year and quarter end dates.
As a result of the announcement of the sale of PC Financial to EQB, the results of PC Financial are presented in discontinued operations, net of intersegment eliminations.
Revenue, included in discontinued operations, in the first quarter of 2026 was $240 million, an increase of $9 million, or 3.9%. The increase was primarily driven by higher interest and interchange income, and higher insurance commission income.Net earnings available to common shareholders of the Company from discontinued operations were $7 million, a decrease of $15 million. The decrease was primarily driven by a charge of $24 million due to a change in certain commodity tax legislation, and higher charge-offs, partially offset by higher revenue described above, and the year-over-year favourable impact of expected credit loss provision. OUTLOOK(3)
Loblaw will continue to execute on retail excellence while advancing its growth initiatives with the goal of delivering consistent operational and financial results in 2026. The Company’s businesses remain well positioned to meet the everyday needs of Canadians. The Company cannot predict the timing of the closing of the Sale of PC Financial, and its impact on the Company’s financial results. In 2026, excluding this impact and the 53rd week impact in 2025, the Company continues to expect:
its Retail business to grow earnings faster than sales;adjusted net earnings per common share(2) growth in the high single-digits;to continue investing in our store network and distribution centres by investing approximately $2.4 billion in gross capital expenditures; andto return capital to shareholders by allocating a significant portion of free cash flow to share repurchases. NORMAL COURSE ISSUER BID PROGRAM (“NCIB”)
During the first quarter of 2026, the Company repurchased 10.2 million common shares for cancellation at a cost of $648 million.
From time to time, the Company participates in an automatic share purchase plan (“ASPP”) with a broker in order to facilitate the repurchase of the Company’s common shares under its NCIB. During the effective period of the ASPP, the Company’s broker may purchase common shares at times when the Company would not be active in the market.
DECLARATION OF DIVIDENDS
Subsequent to the end of the first quarter of 2026, the Board of Directors declared a quarterly dividend of $0.155183 per common share, payable on July 1, 2026 to shareholders of record on June 15, 2026, an increase of 10% from the previous quarterly dividend of $0.141075 per common share paid on April 1, 2026.
NON-GAAP AND OTHER FINANCIAL MEASURES
The Company uses the following non-GAAP and other financial measures and ratios: Adjusted earnings before income taxes, net interest expense and other financing charges and depreciation and amortization (“adjusted EBITDA”); adjusted EBITDA margin; adjusted operating income; adjusted net interest expense and other financing charges; adjusted income taxes; adjusted effective tax rate; adjusted net earnings available to common shareholders; adjusted diluted net earnings per common share, revenue (including Retail and PC Financial), free cash flow, and same-store sales. The Company believes these non-GAAP and other financial measures and ratios provide useful information to both management and investors in measuring the financial performance and financial condition of the Company for the reasons outlined below.
Management uses these and other non-GAAP and other financial measures to exclude the impact of certain expenses and income that must be recognized under GAAP when analyzing underlying consolidated operating performance, as the excluded items are not necessarily reflective of the Company’s underlying operating performance and make comparisons of underlying financial performance between periods difficult. The Company adjusts for these items if it believes doing so would result in a more effective analysis of underlying operating performance. The exclusion of certain items does not imply that they are non-recurring.
These measures do not have a standardized meaning prescribed by GAAP and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with GAAP.
As a result of the announcement of the sale of PC Financial, the results of PC Financial, net of intersegment eliminations, are presented separately as discontinued operations in the Company’s current and comparative results. Unless otherwise indicated, all financial information represents the Company’s results from continuing operations (Retail).
Summary of Non-GAAP and Other Financial Measures
The following table provides a summary of the differences between the Company’s consolidated GAAP and Non-GAAP and other financial measures.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks) GAAP Adjusting
ItemsNon-
GAAP(2) GAAP Adjusting
ItemsNon-
GAAP(2)EBITDA $ 1,629 $ (22)$ 1,607 $1,529 $(20)$1,509Operating income $ 1,010 $ (12)$ 998 $838 $96 $934Net interest expense and other financing charges 181 — 181 162 — 162Earnings before income taxes $ 829 $ (12)$ 817 $676 $96 $772Deduct (add) the following: Income taxes 217 (3) 214 176 29 205Non-controlling interests 25 — 25 19 — 19Net earnings available to common shareholders of the Company from continuing operations $ 587 $ (9)$ 578 $481 $67 $548Net earnings available to common shareholders of the Company from discontinued operations 7 24 31 22 — 22Net earnings available to common shareholders of the Company $ 594 $ 15 $ 609 $503 $67 $570Diluted net earnings per common share(4) ($) $ 0.50 $ 0.02 $ 0.52 $0.42 $0.05 $0.47Continuing operations 0.50 (0.01) 0.49 0.40 0.05 0.45Discontinued operations — 0.03 0.03 0.02 — 0.02Diluted weighted average common shares(4) (millions) 1,178.2 — 1,178.2 1,210.3 — 1210.3 Adjusted Operating Income, Adjusted EBITDA and Adjusted EBITDA Margin The following table reconciles adjusted operating income and adjusted EBITDA to operating income, which is reconciled to net earnings attributable to shareholders of the Company from continuing operations as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted EBITDA is useful in assessing the performance of its ongoing operations and its ability to generate cash flows to fund its cash requirements, including the Company’s capital investment program.
Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025 (millions of Canadian dollars) (12 weeks)
(12 weeks) Net earnings attributable to shareholders of the Company from continuing operations $ 587 $481 Add impact of the following: Non-controlling interests 25 19 Net interest expense and other financing charges 181 162 Income taxes 217 176 Operating income $ 1,010 $838 Add (deduct) impact of the following: Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark $ 10 $116 PC Financial transaction costs 1 — Sale of Wellwise — (5)Gain on sale of non-operating property — (14)Fair value adjustment on fuel, foreign currency contracts and investments (23) (1)Adjusting items $ (12) $96 Adjusted operating income $ 998 $934 Depreciation and amortization 619 691 Less: Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark (10) (116)Adjusted EBITDA $ 1,607 $1,509 Adjusted EBITDA was impacted by the following:
Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark The acquisition of Shoppers Drug Mart in 2014 included approximately $6,050 million of definite life intangible assets, which are being amortized over their estimated useful lives. The annual amortization associated with the acquired intangibles will be approximately $30 million in 2026 and thereafter.
The acquisition of Lifemark in 2022 included approximately $299 million of definite life intangible assets, which are being amortized over their estimated useful lives.
PC Financial transaction costs In the first quarter of 2026, the Company recorded transaction and other related costs of $1 million in connection with the Sale of PC Financial.
Sale of Wellwise In the fourth quarter of 2024, the Company entered into an agreement with a third party to sell all of the shares of its Wellwise business, including 42 Wellwise locations, for cash proceeds and recorded a net fair value write-down of $23 million in SG&A. The transaction closed in the first quarter of 2025 and the Company recorded a gain of $5 million in SG&A.
Gain on sale of non-operating property In the first quarter of 2025, the Company recorded a gain related to the sale of a non-operating property to a third party of $14 million.
Fair value adjustment on fuel, foreign currency contracts, and investments The Company is exposed to commodity price and U.S. dollar exchange rate fluctuations. In accordance with the Company’s commodity risk management policy, the Company enters into exchange traded futures contracts and forward contracts to minimize cost volatility relating to fuel prices and the U.S. dollar exchange rate. These derivatives are not acquired for trading or speculative purposes. Pursuant to the Company’s derivative instruments accounting policy, changes in the fair value of these instruments, which include realized and unrealized gains and losses, are recorded in operating income. Despite the impact of accounting for these commodity and foreign currency derivatives on the Company’s reported results, the derivatives have the economic impact of largely mitigating the associated risks arising from price and exchange rate fluctuations in the underlying commodities and U.S. dollar commitments. The Company holds certain investments, including Venture Fund investments, classified as fair value through profit and loss. Any changes in the fair value of these investments are included in operating income. Starting in the first quarter of 2026, fair value adjustments on such investments are considered an adjusting item. See Section 11 “Non-GAAP and Other Financial Measures” of the Company’s Management’s Discussion and Analysis in the Company’s 2026 First Quarter Report to Shareholders for details regarding the impact of this change to certain Non-GAAP measures.
Adjusted Operating Income from Discontinued Operations, Total Company Adjusted Operating Income, Adjusted EBITDA from Discontinued Operations, Total Company Adjusted EBITDA and Total Company Adjusted EBITDA Margin The following table reconciles adjusted operating income and adjusted EBITDA from discontinued operations to operating income from discontinued operations which is reconciled to net earnings attributable to shareholders of the Company from discontinued operations as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted EBITDA from discontinued operations and on a total Company basis is useful in assessing the performance of its total Company and discontinued operations and its ability to generate cash flows to fund its cash requirements, including the Company’s capital investment program.
Total Company adjusted EBITDA margin is calculated as total Company adjusted EBITDA divided by revenue (including Retail and PC Financial).
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars) (12 weeks)
(12 weeks)Net earnings attributable to shareholders of the Company from discontinued operations(i) $7 $22Add impact of the following: Net interest expense and other financing charges(i) 46 36Income taxes(i) 4 10Operating income from discontinued operations(i) $57 $68Add impact of the following: Charge related to PC Bank commodity tax matter $23 $—Adjusting items $23 $—Adjusted operating income from discontinued operations $80 $68Adjusted operating income (refer to table above) 998 934Total Company adjusted operating income $1,078 $1,002Adjusted operating income from discontinued operations $80 $68Depreciation and amortization from discontinued operations — 14Adjusted EBITDA from discontinued operations $80 $82Adjusted EBITDA (refer to table above) 1,607 1,509Total Company Adjusted EBITDA $1,687 $1,591 (i)For additional information, see note 4 “Assets Held for Sale and Discontinued Operations” of the Company’s interim financial statements. In addition to the items described in the adjusted EBITDA(2) section above, adjusted operating income from discontinued operations and Total Company adjusted operating income were impacted by the following:
Charge related to PC Bank commodity tax matter In the first quarter of 2026, the Federal government enacted commodity tax legislation rendering PC Bank ineligible to claim notional input tax credits for certain payments it makes to Loblaws Inc. in respect of redemptions of loyalty points. As the legislation was effective beginning in fiscal year 2025, PC Bank recorded a charge of $23 million in SG&A, reversing notional input tax credit related amounts previously recorded. In addition, a charge of $10 million was recorded, reversing interest income on expected cash tax refunds.
Adjusted Net Interest Expense and Other Financing Charges The following table reconciles adjusted net interest expense and other financing charges to net interest expense and other financing charges as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted net interest expense and other financing charges is useful in assessing the Company’s underlying financial performance and in making decisions regarding the financial operations of the business.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars) (12 weeks)
(12 weeks)Net interest expense and other financing charges $ 181 $162Adjusted net interest expense and other financing charges $ 181 $162 Adjusted Net Interest Expense and Other Financing Charges from Discontinued Operations The following table reconciles adjusted net interest expense and other financing charges from discontinued operations to adjusted net interest expense and other financing charges from discontinued operations as reported in the notes to the interim financial statements for the periods ended as indicated. The Company believes that adjusted net interest expense and other financing charges is useful in assessing the Company’s underlying financial performance and in making decisions regarding the financial operations of the business.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars)(12 weeks)
(12 weeks)Net interest expense and other financing charges from discontinued operations(i) $ 46 $36Deduct: Charge related to PC Bank commodity tax matter (10) —Adjusted net interest expense and other financing charges from discontinued operations $ 36 $36 (i)For additional information, see note 4 “Assets Held for Sale and Discontinued Operations” of the Company’s interim financial statements. Charge related to PC Bank commodity tax matter In the first quarter of 2026, a charge of $10 million was recorded, reversing interest income on expected cash tax refunds on the PC Bank commodity tax matter as discussed above.
Adjusted Income Taxes and Adjusted Effective Tax Rate The following table reconciles adjusted income taxes to income taxes as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted income taxes is useful in assessing the Company’s underlying operating performance and in making decisions regarding the ongoing operations of its business.
Adjusted effective tax rate is calculated as adjusted income taxes divided by the sum of adjusted operating income less adjusted net interest expense and other financing charges.
For the periods ended March 28, 2026 and March 22, 2025 2026
2025
(millions of Canadian dollars except where otherwise indicated) (12 weeks)
(12 weeks)Adjusted operating income(i) $998 $934 Adjusted net interest expense and other financing charges(i) 181 162 Adjusted earnings before taxes $817 $772 Income taxes $217 $176 Add impact of the following: Tax impact of items included in adjusted earnings before taxes(ii) (3) 29 Adjusted income taxes $214 $205 Effective tax rate 26.2% 26.0%Adjusted effective tax rate 26.2% 26.6% (i)See reconciliations of adjusted operating income and adjusted net interest expense and other financing charges in the tables above.(ii)See the adjusted operating income, adjusted EBITDA and adjusted EBITDA margin table and the adjusted net interest expense and other financing charges table above for a complete list of items included in adjusted earnings before taxes. Adjusted Net Earnings Available to Common Shareholders From Continuing Operations and Adjusted Diluted Net Earnings Per Common Share From Continuing Operations The following table reconciles adjusted net earnings available to common shareholders of the Company from continuing operations and adjusted net earnings attributable to shareholders of the Company from continuing operations to net earnings attributable to shareholders of the Company and then to net earnings available to common shareholders of the Company from continuing operations as reported in the condensed consolidated statements of earnings for the periods ended as indicated. The Company believes that adjusted net earnings available to common shareholders from continuing operations and adjusted diluted net earnings per common share from continuing operations are useful in assessing the Company’s underlying operating performance and in making decisions regarding the ongoing operations of its business.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars except where otherwise indicated) (12 weeks)
(12 weeks)Net earnings attributable to shareholders of the Company $ 594 $503Net earnings from discontinued operations 7 22Net earnings attributable to shareholders of the Company from continuing operations $ 587 $481Net earnings available to common shareholders of the Company from continuing operations $ 587 $481Net earnings attributable to shareholders of the Company from continuing operations $ 587 $481Adjusting items (refer to the following table) (9) 67Adjusted net earnings attributable to shareholders of the Company from continuing operations $ 578 $548Adjusted net earnings available to common shareholders of the Company from continuing operations $ 578 $548Diluted weighted average common shares outstanding(4) (millions) 1,178.2 1,210.3 The following table reconciles adjusted net earnings available to common shareholders of the Company and adjusted diluted net earnings per common share to net earnings available to common shareholders of the Company and diluted net earnings per common share as reported in the condensed consolidated statements of earnings for the periods ended as indicated.
2026 2025 (12 weeks) (12 weeks) Net Earnings
Available to
Common
Shareholders
of the
Company Diluted
Net
Earnings
Per
Common
Share Net Earnings
Available to
Common
Shareholders
of the
Company Diluted
Net
Earnings
Per
Common
Share(4)For the periods ended March 28, 2026 and March 22, 2025
(millions of Canadian dollars/Canadian dollars) Continuing operations $587 $0.50 $481 $0.40 Discontinued operations 7 — 22 0.02 As reported $594 $0.50 $503 $0.42 Continuing operations $587 $0.50 $481 $0.40 Add (deduct) impact of the following: Amortization of intangible assets acquired with Shoppers Drug Mart and Lifemark $7 $— $86 $0.07 PC Financial transaction costs 1 — — — Sale of Wellwise — — (5) (0.01)Gain on sale of non-operating property — — (13) (0.01)Fair value adjustment on fuel, foreign currency contracts, and investments (17) (0.01) (1) — Adjusting items from continuing operations $(9) $(0.01) $67 $0.05 Adjusted continuing operations $578 $0.49 $548 $0.45 Discontinued operations $7 $— $22 $0.02 Add impact of the following: Charges related to PC Bank commodity tax matter $24 $0.03 $— $— Adjusting items from discontinued operations $24 $0.03 $— $— Adjusted discontinued operations $31 $0.03 $22 $0.02 Adjusted Total Company $609 $0.52 $570 $0.47 Revenue (including Retail and PC Financial) The following table reconciles Revenue (including Retail and PC Financial) to Revenue for the periods ended as indicated. Revenue represents retail revenue, and is primarily comprised of Food Retail and Drug Retail sales. The Company believes that Revenue (including Retail and PC Financial) are useful in assessing the Company’s underlying operating performance.
For the periods ended March 28, 2026 and March 22, 2025 2026 2025(millions of Canadian dollars except where otherwise indicated) (12 weeks) (12 weeks)Food Retail(i) $10,238 $9,854Drug Retail 4,246 4,050Pharmacy and healthcare services 2,384 2,201Front store 1,862 1,849Revenue $14,484 $13,904PC Financial revenue (discontinued operations) $240 $231Revenue (including Retail and PC Financial) $14,724 $14,135 (i)As a result of the announcement of the sale of PC Financial, Food Retail sales now includes revenue related to PC Services, primarily related to sales attributable to The Mobile Shop™ in the current and comparative period presented, including revenue of $69 million in the first quarter of 2026 (2025 – $67 million). Free Cash Flow The following table reconciles cash flows from operating activities to free cash flow. The Company believes that free cash flow is the appropriate measure in assessing the Company’s cash available for additional financing and investing activities.
2026 2025 (12 weeks) (12 weeks)For the periods ended March 28, 2026 and March 22, 2025 Continuing Operations
Discontinued Operations
Total
Continuing Operations
Discontinued Operations
Total
(millions of Canadian dollars) Cash flows from operating activities $ 1,096 $ 212 $ 1,308 $412 $541 $953Less: Capital investments(i) 305 7 312 237 9 246Interest paid 87 16 103 87 20 107Lease payments, net 272 — 272 385 — 385Free cash flow(2) $ 432 $ 189 $ 621 $(297) $512 $215 (i) Capital investments are the sum of fixed asset purchases and intangible asset additions as presented in the Company’s condensed consolidated statements of cash flows, and prepayments transferred to fixed assets in the current period. Same-Store Sales Same-store sales are retail sales for stores in operation in both comparable periods, including relocated, converted, expanded, contracted or renovated stores. The Company believes this metric is useful in assessing sales trends excluding the effect of the opening and closure of stores.
FORWARD-LOOKING STATEMENTS
This News Release contains forward-looking statements about the Company’s objectives, plans, goals, aspirations, strategies, financial condition, results of operations, cash flows, performance, prospects, opportunities and legal and regulatory matters. Specific forward-looking statements in this News Release include, but are not limited to, statements with respect to the Company’s anticipated future results, events and plans, strategic initiatives and restructuring, regulatory changes including further healthcare reform, future liquidity, planned capital investments, and the status and impact of IT systems implementations. These specific forward-looking statements are contained throughout this News Release including, without limitation, in the “Consolidated Results of Operations”, “Retail Results (Continuing Operations)”, “PC Financial Results (Discontinued Operations)”, and “Outlook” sections of this News Release. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may”, “should” and similar expressions, as they relate to the Company and its management.
Forward-looking statements reflect the Company’s estimates, beliefs and assumptions, which are based on management’s perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. The Company’s estimates, beliefs and assumptions are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and, as such, are subject to change. The Company can give no assurance that such estimates, beliefs and assumptions will prove to be correct.
Numerous risks and uncertainties could cause the Company’s actual results to differ materially from those expressed, implied or projected in the forward-looking statements, including those described in the Company’s Management Discussion & Analysis (“MD&A”) in the 2025 Annual Report, and the Company’s Annual Information Form (“AIF”) for the year ended January 3, 2026.
Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company’s expectations only as of the date of this News Release. Except as required by law, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CORPORATE PROFILE
2025 Annual Report and 2026 First Quarter Report to Shareholders
The Company’s 2025 Annual Report and 2026 First Quarter Report to Shareholders are available in the “Investors” section of the Company’s website at loblaw.ca and sedarplus.ca.
InvestorsMediaRoy MacDonaldScott BonikowskyVice President, Investor RelationsSenior Vice President, Corporate Affairs and [email protected]@loblaw.ca Additional financial information has been filed electronically with various securities regulators in Canada through SEDAR+ and with the Office of the Superintendent of Financial Institutions (OSFI) as the primary regulator for the Company’s subsidiary, PC Bank. The Company holds an analyst call shortly following the release of its quarterly results. These calls are archived in the “Investors” section of the Company’s website at loblaw.ca.
Conference Call and Webcast
Loblaw will host a conference call as well as an audio webcast on May 6, 2026 at 10:00 a.m. (ET).
To access via audio webcast please go to the “Investors” section of loblaw.ca, and note that pre-registration will be available. Alternatively, please dial (647) 932-3411 or Toll-Free (800) 715-9871. Following the live event, the webcast will be archived and available to replay for 12 months.
Full details about the conference call and webcast are available on the Loblaw website at loblaw.ca.
Annual Meeting of Shareholders
The 2026 Annual Meeting of Shareholders of Loblaw Companies Limited will be held on Tuesday, May 12, 2026 at 10:00 a.m. (ET) at Massey Hall, 178 Victoria Street, Toronto, Ontario, Canada and virtually via a live webcast.
Shareholders will also be able to listen, participate and vote at the meeting in real time through a live webcast online at https://meetings.lumiconnect.com/400-240-280-696 (meeting password: agm2026). See “Questions and answers on attending and voting virtually” in the Management Proxy, which can be viewed online at www.loblaw.ca or under Loblaw’s SEDAR+ profile at www.sedarplus.ca, for detailed instructions on how to attend and vote at the meeting.
Please refer to the “Events and Presentations” or “Shareholders Services” page at loblaw.ca for additional details on the virtual meeting.
News Release Endnotes (1) This News Release contains forward-looking information. See “Forward-Looking Statements” section of this News Release and the Company’s 2026 First Quarter Report to Shareholders for a discussion of material factors that could cause actual results to differ materially from the forecasts and projections herein and of the material factors and assumptions that were used when making these statements. This News Release should be read in conjunction with Loblaw Companies Limited’s filings with securities regulators made from time to time, all of which can be found at sedarplus.ca and at loblaw.ca.
(2) See “Non-GAAP and Other Financial Measures” section of this News Release, which includes the reconciliation of such non-GAAP and other financial measures to the most directly comparable GAAP measures.
(3) To be read in conjunction with the “Forward-Looking Statements” section of this News Release and the Company’s 2026 First Quarter Report to Shareholders.
(4) Adjusted to reflect the four-for-one stock split effective at the close of business on August 18, 2025. For additional information, see note 10 “Share Capital” of the Company’s interim financial statements.
May 06, 2026 06:45 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, May 06, 2026 (GLOBE NEWSWIRE) -- (TSX: L) – Loblaw Companies Limited (Loblaw) announced today that the Toronto Stock Exchange (TSX) has accepted a notice filed by Loblaw of its intention to make a normal course issuer bid (NCIB).
The TSX notice provides that Loblaw may, during the 12-month period commencing May 8, 2026 and terminating May 7, 2027, purchase up to 58,124,733 of Loblaw’s common shares (Common Shares), representing approximately 5% of the issued and outstanding Common Shares, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted by the TSX or under applicable law. As of April 30, 2026, Loblaw had 1,162,494,675 outstanding Common Shares. Based on the average daily trading volume of 1,248,481 during the last six months, daily purchases will be limited to 312,120 Common Shares, other than block purchase exceptions and purchases from George Weston Limited (GWL), Loblaw’s majority shareholder.
In accordance with an exemption granted by the TSX pursuant to its rules, regulations and policies in connection with the NCIB, GWL will participate in the NCIB on a basis proportionate to its percentage ownership interest in Loblaw, which is consistent with the exemption granted by the TSX each year since 2020. Such participation eliminates the accretive effect that the NCIB would otherwise have on GWL’s percentage ownership interest in Loblaw. The maximum number of Common Shares that may be purchased pursuant to the NCIB will be reduced by the number of Common Shares purchased by Loblaw from GWL.
Purchases of Common Shares will be made in open market transactions on the TSX or through alternative trading systems. In addition, Loblaw may enter into forward purchase or swap contracts in connection with Common Shares which may be settled by physical settlement, cash settlement or a combination thereof, in each case subject to regulatory approval, if required, and on such terms and at such times as shall be permitted by applicable securities laws. The forward price will be based on market price, dividend yield and market interest rates. Loblaw may also purchase Common Shares through private agreements or share repurchase programs if it receives an issuer bid exemption order permitting it to make such purchases. Any purchases of Common Shares made by way of private agreements or under share repurchase programs may be at a discount to the prevailing market price as provided in the relevant issuer bid exemption order.
Purchases from GWL will be made during the TSX’s Special Trading Session pursuant to an automatic disposition plan agreement between Loblaw’s broker, Loblaw and GWL (ADP Agreement). Purchases from GWL will be made on trading days, as required by the ADP Agreement, that Loblaw makes a purchase from other shareholders. In the event that GWL does not sell Common Shares on any trading day as required by the terms of the ADP Agreement (other than as a result of a market disruption event), the TSX exemption will cease to apply and Loblaw will not be permitted to make any further purchases from GWL under the terms of the NCIB.
Decisions regarding the timing of future purchases of Common Shares will be based on market conditions, share price and other factors. Loblaw may elect to suspend or discontinue its NCIB at any time, subject to the terms of any automatic purchase plan then in place. Common Shares purchased under the NCIB will be cancelled or used in connection with the settlement of restricted share units or performance share units. Loblaw believes that the market price of Common Shares could be such that their purchase may be an attractive and appropriate use of corporate funds. Loblaw may also use its NCIB to acquire the number of Common Shares that are issued pursuant to the exercise of options in order to offset the dilutive effect of options that have been exercised. Under its prior NCIB that commenced on May 6, 2025 and expired on May 5, 2026, Loblaw had sought and received approval from the TSX to purchase up to 59,800,244 Common Shares. As of April 30, 2026, Loblaw has purchased 36,885,504 Common Shares under its prior NCIB through open market purchases on the TSX and exempt private agreement purchases, at a weighted average price of $59.85.
From time to time, when Loblaw does not possess material non-public information about itself or its securities, it may enter into a pre-defined plan with its broker to allow for the purchase of Common Shares at times when Loblaw ordinarily would not be active in the market due to its own internal trading blackout periods and insider trading rules. Any such plans entered into with Loblaw’s broker will be adopted in accordance with the requirements of applicable Canadian securities laws. Loblaw intends to enter an automatic share purchase plan with a broker on or about May 8, 2026, in order to facilitate repurchases under the NCIB.
About Loblaw Companies Limited
Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy and health services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers.
Loblaw's purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; affordable Joe Fresh® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw's website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
For more information contact: Roy MacDonald, Vice President, Investor Relations, (905) 861-2243, [email protected]
May 12, 2026 07:00 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L) released its 2025 Live Life Well® report, highlighting the Company’s continued progress across environmental, social, and governance (ESG) priorities.
As a proudly Canadian food and health care company, Loblaw remains committed to helping Canadians prosper today and for generations to come. This commitment is reflected in ongoing efforts to address climate change, advance social equity, and support communities across the country.
“As a generational Canadian company, we are deeply rooted in the communities we serve,” said Per Bank, President and CEO, Loblaw Companies Limited. “Across more than 2,800 stores, our Franchisee Owners, Associate Owners, Managers, Pharmacists and colleagues live where they work. They understand the realities facing their neighbours, and that proximity shapes how we respond to social challenges, climate impacts, and the everyday needs of the millions of Canadians who rely on us.”
In 2025, Loblaw continued to advance its ESG priorities through initiatives that included improving food access, advancing responsible sourcing, strengthening climate resilience, and supporting health equity.
Key highlights from 2025 include:
Reduced food waste by donating more than 20,000 metric tonnes of food to food banks and recovery organizations. Strengthened responsible sourcing efforts through ongoing partnerships with Canadian suppliers and initiatives that aim to protect ecosystems. Advanced climate action by investing in renewable energy, reducing emissions, and redesigning packaging to improve the recyclability of thousands of products.Raised and donated more than $23.7 million to President’s Choice Children’s Charity, supporting school food programs that reached one million children. Raised and donated more than $18.7 million to the Shoppers Foundation for Women’s Health, supporting health equity for all women in Canada. Opened 250 Pharmacy Care Clinics, improving access to care in the communities we serve. Read the full 2025 Live Life Well® report at https://www.loblaw.ca/en/responsibility/.
NEW YORK, May 12, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable June 9, 2026 to shareholders of record as of the close of business on May 27, 2026.
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries. For more information please visit www.loews.com.
May 12, 2026 21:40 ET | Source: Loblaw Companies Limited
BRAMPTON, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- (TSX: L) – Loblaw Companies Limited (Loblaw) announced today that all of the nominee directors listed in the management proxy circular dated March 30, 2026, were elected as directors of Loblaw. The vote was conducted at the Company's Annual Meeting of Shareholders, held at Massey Hall, 178 Victoria St, Toronto, Ontario, Canada, and online through a web-based platform, on May 12, 2026. The results of the vote are set out below:
Name of NomineeVotes ForVotes AgainstScott B. Bonham1,015,339,641 99.73% 2,723,661 0.27% Shelley G. Broader1,017,290,216 99.92% 773,087 0.08% Christie J.B. Clark999,717,774 98.20% 18,345,528 1.80% Daniel Debow1,016,068,995 99.80% 1,994,308 0.20% William A. Downe991,665,508 97.41% 26,397,795 2.59% Janice Fukakusa1,012,779,028 99.48% 5,284,275 0.52% M. Marianne Harris1,015,285,319 99.73% 2,776,783 0.27% Kevin Holt1,017,188,239 99.91% 875,064 0.09% Claudia Kotchka1,015,245,868 99.72% 2,817,434 0.28% Rima Qureshi1,017,188,006 99.91% 875,297 0.09% Sarah Raiss1,014,842,307 99.68% 3,220,995 0.32% Galen G. Weston996,740,679 97.91% 21,322,622 2.09% Cornell Wright1,008,044,516 99.02% 10,018,786 0.98% About Loblaw Companies Limited
Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy and health services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers.
Loblaw's purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; affordable Joe Fresh® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw's website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
For more information contact: Roy MacDonald, Vice President, Investor Relations, [email protected].
BRAMPTON, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Being an Insider is all about the thrill of discovery, that can’t-wait-to-see-what’s-next energy. Here at President’s Choice, we’re always pushing new taste possibilities. The goal? Make this your most delicious summer yet.
“Summer starts now, and this year, we didn’t hold back,” says Mary MacIsaac, EVP & Chief Marketing Officer at Loblaw Companies Limited. “The PC® Summer Insiders Report™ is our most exciting collection yet, packed with bold new tastes that have been thoughtfully inspired, endlessly tested, and taken even further. One idea sparked another, and before we knew it, we had something truly special: the ultimate taste of summer.”
“We’re always after the next great bite," adds MacIsaac. “From products that took years to perfect, like our PC® Jerk Chicken Burger to hand-selected, fresh ingredients sourced and grown to our exacting PC® standards, every detail matters."
Speaking of not holding back, we had so many amazing PC® Must Tries, we couldn’t decide which was most worthy of the coveted front cover status… so we didn’t choose just one. For the first time in Insiders history, President’s Choice is unveiling four front covers. Team Burger or Team Sausage? Dessert or Fresh Fruit? Collect them all and let the friendly debates begin. No matter which side you pick, there’s one undeniable truth: summer belongs to Insiders.
More Memories
Turn everyday moments into unforgettable summer memories
Put something new on the 'cue with the PC® Sizzle Wheel Shrimp. Choose from Chili Crisp with tingly Szechuan pepper extract or go classic with Garlic & Herb. Slide onto the grill, sizzle, and serve straight from the tray for summer's can’t-miss stunner.Make peak-summer produce an everyday occasion with PC® greenhouse-grown tomatoes. Many of our tomatoes are grown in Leamington, ON—home to North America’s largest concentration of greenhouses—where they’re cultivated for exceptional flavour, all year round. Taste Escapes
Travel through taste with PC® flavour forays and gear that bring the escape to you.
PC® World of Flavour Chips celebrate Canada's most iconic tastes, from east to west. Crunch into Spicy Caesar, Peameal Bacon, Poutine, and Halifax’s Donair. Made with all-Canadian potatoes, these chips are a delightful reminder that there’s truly no taste like home.PC® Perfectly Portable Tabletop Grill - Full-size grill performance packed into a grill that moves with you. Complete with a prep tray and a lid that doubles as a food-grade bamboo cutting board. No matter where you go, make the destination delicious. Balanced Bliss
Wellness wins that taste as good as they feel, and flavours that spark joy, not second thoughts.
PC® Scoop Shop Ice Creams channel old-school ice cream parlour energy without artificial flavours or synthetic colours. Crafted with 100% Canadian dairy, raise a cone to the latest flavours: Rainbow Trail, Cookie Dough, and Pina Colada.Whether it’s soda without the sugar or fizz you can feel good about, PC® is all about pushing the bubble further. Meet PC® Blue Menu Passionfruit Guava Flavoured Sparkling Water: tangy, tropical, and a fresh twist on sparkling sips. Discover the full PC® Summer Insiders Report™, featuring new product innovation, recipes and fresh ideas—plus an immersive, scroll-stopping experience on the PC Optimum™ App and banner sites that bring it all to life. Products are also available at participating stores, including Real Canadian Superstore, No Frills, Maxi, Your Independent Grocer, Real Atlantic Superstore, Loblaws, Zehrs, Fortinos, Provigo, valu-mart, Dominion Stores in Newfoundland and Labrador and Shoppers Drug Mart/Pharmaprix.
PC Optimum® members can unlock even more value all summer long with exclusive offers and rewards on featured PC® products.
About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.
Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market™, no name® and President's Choice®. For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw's issuer profile at www.sedarplus.ca.
A video accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cf32ae23-3969-4dfd-8149-a7d44c38252c
President’s Choice unveils its annual PC® Summer Insiders Report™ Being an Insider is all about the thrill of discovery, that can’t-wait-to-see-what’s-next energy. He...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapy. The European Commission decision on the additional Trodelvy indication is anticipated later in 2026.
Metastatic TNBC is an aggressive form of breast cancer that is associated with low survival rates. For many patients with metastatic TNBC, first-line therapy may be their only line of treatment, necessitating an urgency to act using the most effective treatment options first to maximize patient outcomes.
“Metastatic TNBC remains one of the most challenging breast cancer subtypes to treat, particularly at the time of first diagnosis of advanced disease, when therapeutic options are limited for many patients,” said Dr. Javier Cortes, Head of the International Breast Cancer Center, Madrid and Barcelona, Spain. “The CHMP’s positive opinion for sacituzumab govitecan represents an important step towards potential approval in this setting and reflects the clinically meaningful results observed in the ASCENT-03 study. Advancing effective treatment options earlier in the disease course is critical to improving outcomes for people living with metastatic TNBC.”
The CHMP’s recommendation is based on data from the Phase 3 ASCENT-03 study which demonstrated a highly statistically significant and clinically meaningful progression-free survival of Trodelvy compared to standard of care chemotherapy as a first-line treatment. In ASCENT-03, Trodelvy demonstrated a 38% reduced risk of disease progression or death in patients who are not candidates for PD-1/PD-L1 inhibitors. Gilead has also submitted an application to the U.S. Food and Drug Administration for approval of Trodelvy in this indication based on the ASCENT-03 study.
“This CHMP positive opinion for Trodelvy represents a pivotal moment for people with metastatic TNBC across Europe, and we look forward to hearing from the European Medicines Agency,” said Mika Kakefuda Derynck, MD, Senior Vice President, Clinical Development, Oncology at Gilead Sciences. “Building on the extensive clinical experience with Trodelvy in later lines of therapy, this recommendation has the potential to fundamentally change how we approach treating certain first-line metastatic TNBC patients, offering a much-needed option earlier in care when it can make the greatest difference. Each step forward means more options and more chances to change the story for people living this cancer.”
Gilead has also submitted supplemental filings to the European Medicines Agency and the U.S. Food and Drug Administration for Trodelvy in combination with Keytruda® (pembrolizumab) for patients with PD-L1 positive unresectable locally advanced or metastatic TNBC, based on data from the Phase 3 ASCENT-04 study. These applications are currently under review. If approved, Trodelvy has the potential to be a backbone treatment in 1L mTNBC, across PD-L1 status.
Trodelvy is currently approved as a second-line plus treatment for metastatic TNBC and for patients with pre-treated HR+/HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) metastatic breast cancer. Healthcare professionals have substantial clinical experience with Trodelvy, with more than 75,000 breast cancer patients treated across 60+ countries since 2020. It remains the only Trop-2-directed ADC to demonstrate meaningful overall survival benefits in both second-line or later metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer. It is also the only ADC with four positive Phase 3 trials in HER2-negative metastatic breast cancer (mBC).
The use of Trodelvy plus pembrolizumab in patients with first-line PD-L1+ metastatic TNBC and Trodelvy as monotherapy in patients with first-line metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitors are investigational, and the safety and efficacy of these uses have not been established.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About Triple-Negative Breast Cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for approximately 15% of all breast cancers. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited HER2 expression. Due to the nature of TNBC, treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of mBC.
About Trodelvy
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect.
Trodelvy is currently approved in more than 60 countries for second-line or later metastatic triple-negative breast cancer (TNBC) and in more than 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer (mBC). Outside of Europe, Gilead has submitted supplemental applications to the U.S. Food and Drug Administration (FDA) for approval of Trodelvy based on the ASCENT-03 and ASCENT-04 studies.
Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across a range of tumor types with high Trop-2 expression. These studies with Trodelvy, both in monotherapy and in combination with pembrolizumab, involve earlier lines of treatment for TNBC and HR+/HER2- breast cancer—including in curative settings—as well as in lung and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.
U.S. INDICATIONS FOR TRODELVY
TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. U.S. IMPORTANT SAFETY INFORMATION FOR TRODELVY
BOXED WARNING: NEUTROPENIA AND DIARRHEA
TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. CONTRAINDICATIONS
Severe hypersensitivity reaction to TRODELVY. WARNINGS AND PRECAUTIONS
Neutropenia: Severe, life-threatening, or fatal neutropenia can occur as early as the first cycle of treatment and may require dose modification. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities. Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm3 on Day 1 of any cycle or below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 of USPI.
Diarrhea: Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤ Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.
Hypersensitivity and Infusion-Related Reactions: TRODELVY can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.
Nausea and Vomiting: TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 64% of all patients treated with TRODELVY and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤ 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.
Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.
Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.
ADVERSE REACTIONS
In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).
In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.
In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.
DRUG INTERACTIONS
UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.
UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.
Please see full Prescribing Information, including BOXED WARNING.
About Gilead and Kite Oncology
Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving Trodelvy; uncertainties relating to regulatory applications and related filing and approval timelines, including such as the pending applications for Trodelvy in 1L mTNBC and potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
U.S. Prescribing Information for Trodelvy, including BOXED WARNING, is available at www.gilead.com.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
